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Abstract 
 
   Previously, our lab demonstrated that heterologous immunity could result 
in either gain or loss of protective immunity and alteration in immune pathology 
following infection by a second un-related pathogen.  One of the prototypical 
models to study T cell-mediated heterologous immunity involves two distantly 
related arenaviruses, namely lymphocytic choriomeningitis virus (LCMV) and 
Pichinde virus (PV).  Each virus encodes a cross-reactive CD8 epitope that has 
six out of eight in amino acid (aa) similarity with respect to its counterpart at the 
position 205-212 of the nucleoprotein (NP205).  Heterologous challenge between 
LCMV and PV results in 1) expansion of the cross-reactive NP205-specific CD8 
T cell responses and alteration of the immunodominance hierarchy and 2) partial 
protective immunity (heterologous immunity). 
 Our lab showed that cross-reactive NP205-specific CD8 T cell receptor 
(TCR) repertoires become extremely narrowed following a heterologous 
challenge between LCMV and PV.  Therefore, I questioned if LCMV NP205 
epitope escape variants could be isolated during a dominant but narrowed cross-

reactive NP205-specific CTL response.  In the first part of my thesis, I describe 
the isolation of a LCMV NP-V207A CTL escape variant in vivo using PV-immune 
animals challenged with LCMV clone 13.  The LCMV NP-V207A variant contains 
a point mutation, which results in the switching of valine to alanine at the third 
non-anchoring residue of the LCMV NP205 CD8 epitope.  Immunization of mice 
with the LCMV NP-V207A variant results in a significantly diminished cross-
reactive NP205-specific CD8 T cell response.  This suggests that the point 
mutation is responsible for the loss in the immunogenicity of the LCMV NP205 
CD8 epitope.  In addition, an in vitro rescued(r) recombinant LCMV variant 
(r/V207A) that encodes the original mutation also induces a highly diminished 
cross-reactive NP205-specific CD8 T cell response in mice.  In agreement with 
the result obtained from the intracellular cytokine assays (ICS), MHC-Ig dimers 
loaded with the LCMV NP205 (V-A) peptide could only detect a minute 
population of cross-reactive NP205-specific CD8 T cells in mice infected with 
r/V207A variant virus.  All the data indicate that the point mutation results in a 
significant loss in immunogenicity of the LCMV NP205 CD8 epitope. 

 So far, no direct link between the cross-reactive NP205-specific CD8 T 
cells and heterologous immunity had been established in this system. Therefore, 
we immunized mice with either LCMV WT or the LCMV NP-V207A variant virus 
and showed that a significant loss of heterologous immunity is associated with 
the group immunized with LCMV NP-V207A variant virus.  Again, r/V207A-
immune animals also displayed a significant loss in heterologous immunity 
following PV challenge.  This suggests that the cross-reactive NP205-specific 
CD8 T cells mediate the majority of heterologous immunity between LCMV and 
PV in vivo.  In comparison to the PV-immune control group, PV clearance 
kinetics mediated by the cross-reactive NP205-specific CD8 T cells were 
significantly delayed.  Finally, these data also suggest that bystander activation 
plays very little role in heterologous immunity between LCMV and PV. 
 Many studies in murine systems and humans suggest that cross-reactive 
T cells are often associated with immune pathology.  We showed that in mice 
that were sequentially immunized with PV and LCMV (PV+LCMV WT double 
immune mice), there was a development of a high incidence and high level of 
immune pathology known as acute fatty necrosis (AFN) following a final PV 

challenge.  The data suggest that these cross-reactive NP205-specific CD8 T 
cells might play an important role in immune pathogenesis. Therefore, we asked 
if the cross-reactive NP205-specific CD8 T cells play a role in immune 
pathogenesis by comparing the incidence of AFN between the (PV+LCMV WT) 
and the (PV+LCMV NP-V207A) double immune mice following a final PV 
challenge.  In agreement with our hypothesis, the result showed the (PV+LCMV 
NP-V207A) double immune mice developed a significantly lower incidence of 
AFN compared to the (PV+LCMV WT) double immune mice.  However, linear 
correlation studies comparing the frequency of different antigen-specific CD8 T 
cell populations within the (PV+LCMV WT) double immune mice before 
challenge and the severity of AFN following the PV challenge suggest that two 
opposing antigen-specific CD8 T cell populations are involved in determining the 
final outcome of the immune pathology.  The PV NP38-45-specific CD8 T cell 
response (PV NP38) appears to be more protective than the cross-reactive 
NP205-specific CD8 T cell response.  In addition, a positive linear correlation 
between the ratio of cross-reactive NP205 to PV NP38 and the severity of AFN 
seem to suggest that these cross-reactive populations are important contributors 

to immune pathogenesis.  Peptide titration studies examining the functional 
avidities to different antigenic specificities suggest that both populations consist 
of high avidity TCR and peptide MHC (TCR:pMHC) interactions.  However, 
skewing within the cross-reactive NP205 specific CD8 T cell response towards 
the LCMV NP205 epitope response in one of the (PV+LCMV WT) double 
immune mice suggests that cross-reactive NP205 specific CD8 T cells could 
constitute a sub-optimal response to a PV challenge.  
 In summary, I questioned what might be some of the immunological 
consequences of heterologous immunity in this model.  First of all, we have 
established a direct link between the cross-reactive NP205-specific CD8 T cell 
response and heterologous immunity in LCMV and PV.  Second of all, I 
demonstrated that a LCMV NP205 epitope escape variant could be selected in 
vivo under the conditions of heterologous immunity.  In addition, I showed that 
PV clearance kinetic was significantly delayed in cross-reactive NP205-mediated 
heterologous immunity as compared to homologous challenge.  Finally, we 
demonstrated that cross-reactive NP205-specific CD8 T cells could play an 
important role in immune pathogenesis in this model.  However, correlation data 
indicate that two opposing antigen-specific CD8 T cell populations could 
ultimately decide the outcome and magnitude of immune pathology in each 
individual mouse. All the data presented above strongly suggest that the cross-
reactive NP205 CD8 T cells play a crucial role in immune pathology in this model 
system by 1) interfering with the regular establishment of immunodominance 
hierarchy orders, or 2) exhibiting a sub-optimal protective immunity due to the 
nature of the cross-reactive epitope. 
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Chapter I 
 
Introduction 
 
 
A.  T cell Cross-Reactivity 
Memory lymphocytes represent an important hallmark of our mammalian 
adaptive immunity.  Unlike naïve lymphocytes that require a certain number of 
cell divisions to acquire necessary effector functions, memory lymphocytes are 
able to respond to the same antigenic determinants in a swift manner, thereby 
dramatically slowing down the progress of re-infection (Veiga-Fernandes et al., 
2000).  Historically, cross-reactive antibodies have been suggested in the 
modulation of viral infections and autoimmune diseases.  For example, a 
phenomenon called “original antigenic sin” was first described where cross-
reactive antibodies from a previous influenza A viral strain (IAV) could bias the 
development of more protective neutralizing antibodies from a newly infecting 
strain (Virelizier et al., 1974).  In addition, non-neutralizing antibodies specific to 
one serotype of dengue virus have been suggested to mediate “immune 
enhancement” by binding to a second dengue serotype and facilitate infection 
(Morens and Halstead, 1990).  Heterologous immunity mediated by the cross-
reactive T cell responses has been shown to lead to either accelerated or 
delayed viral clearance and altered immune pathology (Chen et al., 2003; Selin 
et al., 1998).  Thus, the study of cross-reactive T cell response is crucial in 
understanding the nature of diseases as well as future vaccine designs. 
T cell receptors (TCRs) are important in recognition of antigens that are 
synthesized inside a cell, and they share a very similar structure with 
immunoglobulin made by B cells.  A typical TCR is composed of alpha and beta 
chains.  Each chain is composed of a variable and a constant region.  Like B 
cells, the diversity of the T cell repertoire derives from the ability to undergo 
somatic recombination between different segments of the variable regions (Chien 
et al., 1984).  Given the constraint on the overall size of the immune system to 
generate sufficiently diverse TCR repertoires to recognize all the potential 
epitopes, a TCR needs to be both specific and degenerate at the same time 
(Wilson et al., 2004).  It has been calculated that in order to have a murine T cell 
repertoire that can recognize potentially any given foreign epitopes, a single TCR 
must be able to recognize up to 105 to 106 peptide-MHC combinations (Mason, 
1998).  Otherwise, the murine immune system would need to be significantly 
larger if it is to follow the “one clone, one antigen” rule to obtain a naïve T cell 
pool that can recognize potentially any given epitope.  Therefore, T cell “poly-
specificity” must be an essential feature of the TCR repertoire in which a single 
TCR can be degenerate enough to recognize myriads of epitopes while 
maintaining its ignorance to self-antigens (Wucherpfennig et al., 2007).  Finally, a 
balance between TCR specificity and degeneracy is the key aspect in studying 
the T cell cross-reactive response. 
T cell cross-reactivity can be categorized into different levels.  Due to the 
inherent cross-reactivity of the TCR with the self-peptide MHC (pMHC), allo-
reactive T cells in the recipients usually present a significant tissue 
transplantation barrier (Archbold et al., 2008; Molina and Huber, 1990).  In fact, it 
has been estimated that approximately 1% to 10% of the naïve CD8 T cells are 
allo-specific (Brehm et al., 2007; Suchin et al., 2001).  Virus-specific CD8 T cells 
generated following a viral infection displayed a strong association with allograft 
rejections (Brehm et al., 2005; Welsh et al., 2000).  A similar report also suggests 
that CMV-specific CD8 T cells in human can also cross-react with allo-pMHC, 
which might be one of the reasons why CMV-infection is often associated with 
high incidence of graft-rejections (Gamadia et al., 2004).    
In addition, cross-reactive T cells are often major participants in 
autoimmune diseases.  T cell epitope “molecular mimicry”, a term that is often 
used to describe foreign pathogenic epitopes that closely resemble self-peptides, 
has been postulated to be one of the mechanisms of autoimmune diseases.  For 
example, a study by Croxford et al suggested that molecular mimicry could play a 
critical role in the induction of autoimmune disease in the MS model.  They 
showed infection of mice with a non-pathogenic strain of Theiler’s murine 
encephalomyelitis virus encoding a Haemophilus influenzae epitope, which 
shares 6/13 amino acid (aa) similarity with the dominant myelin proteolipid 
protein epitope (PLP 139-151), induced disease in the CNS (Croxford et al., 
2006).  In humans, epitope molecular mimicry between cardiac myosin and the 
streptococcal M protein has been implicated in the pathogenesis of rheumatic 
heart disease by cross-reactive T cells (Ellis et al., 2005).  Finally, a mouse 
dopamine beta-mono-oxygenase peptide, which shares 44% in aa sequence 
similarity with LCMV immunodominant peptide GP33-41 (GP33), has been 
	suggested as a cross-reactive self-ligand (Ohteki et al., 1999).  Furthermore, 
there is also evidence showing that Epstein-Barr nuclear antigen (EBNA)-specific 
T cells from Epstein-Barr virus (EBV) infected individuals could also contribute to 
the development of multiple sclerosis by cross-reacting with myelin antigen 
(Lünemann et al., 2008). 
The third category of T cell cross-reactivity involves antigenic 
determinants derived from either related or un-related pathogens.  For example, 
CD8 T cell cross-reactivity has been observed between two epitopes from the 
middle T antigen in polyomavirus (Wilson et al., 1999).  The authors suggest that 
this immunodominant, broad cross-reactivity could play a role in prevention of 
CTL escape variants and tumor escape variants.  In addition, CD8 T cell cross-
reactivity has also been reported between two epitopes from different proteins 
from the same virus (Kuwano et al., 1991).  Specifically, my thesis work will focus 
on T cell cross-reactivity between two distantly related viruses.  This type of T 
cell cross-reactivity could have significant impact on the overall composition of 
the host immune repertoire and bears significant implications on the future of 
vaccine design.   

Cross-reactive CD8 epitopes between LCMV and PV have been 
previously identified.  Heterologous challenge between LCMV and PV results in 
modulation of the immunodominance hierarchy (Brehm et al., 2002).  The LCMV 
NP205  (YTVKYPNL) and PV NP205 (YTVKFPNM) epitopes are both Kb-
restricted and differ only in two of the aa anchoring residues.  The T cell cross-
reactivity between these two distantly related viruses has been shown to be bi-
directional, highlighting the structural similarities between these two epitopes.  
The crystal structures of the LCMV and PV NP205 peptide-MHC complexes were 
solved by our collaborators in Australia.  A comparison of the overall structure 
between the LCMV and PV NP205 peptide complexes suggest that there are 
changes in the conformation of the amino terminal residues (P1-P4), with a 
marked change in P4 Lys (K) (Fig 1.1).  Further analysis suggests that there is a 
significant movement at the amino terminus of the LCMV NP205 epitope as 
compared to the PV NP205 epitope (Fig 1.1).  Overall, PV NP205 seems to be 
more stable (Fig 1.1).  A closer look at the anchoring residue at P5 supports the 
hypothesis that PV NP205 might be more stable.  The P5 Phe (F) of the PV 
NP205 epitope fits very nicely to the anchoring pocket (Fig 1.1).  On the other 
hand, the hydroxyl group at the end of Tyr (Y) from the LCMV NP205 epitope 
pushes the residues in the anchoring pocket away from the peptide residue, 
which results in changes in the P4 Lys conformation (Fig 1.1).  Thus, despite the 
high aa sequence similarity between the LCMV and PV NP205 CD8 epitopes, 
the T cell repertoires that are required to recognize each distinct epitope might be 
quite different.  In fact, we have learned that the majority of the LCMV NP205-
specific CD8 T cells have a preferential usage of Vb16, whereas the PV NP205-
specific CD8 T cells share between Vb5.1/5.2 and Vb16 usage (Cornberg et al., 
2006).  In the LCMV and vaccinia virus (VV) model, a VV cross-reactive epitope 
has also being identified based on the concept of molecular mimicry to the LCMV 
NP205 epitope (Cornberg et al., 2007). The VV-encoded, subdominant Kb-
restricted epitope called A11R 198-206 (AIVNYANL) is 50% in aa sequence 
similarity to the LCMV NP205 epitope. 
The T cell cross-reactivity between LCMV and VV involves multiple 
LCMV-specific memory populations.  The cross-reactive expansion of NP205-
specific CD8 T cells are observed most frequently (50%), followed by GP34-41-
specific CD8 T cell populations (23%), and GP118-125 specific CD8 T cell 
populations (15%) among the different LCMV-immune mice challenged with VV 
(Selin et al., 2006).  This reflects the private TCR repertoire of each individual 
host, a term we refer to as private specificity (Kim et al., 2005; Lin and Welsh, 
1998).  It has been shown that even in mice that share the same genetic 
background, their naïve T cell repertoires are not completely identical (Bousso et 
al., 1998).  Therefore, private specificity reflects the variations in length and 
sequence diversity within the complementary determining region 3 (CDR3) due 
to a random insertion of p and n nucleotides during end joining and could play an 
important role in heterologous immunity (Kedzierska et al., 2008). 
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B.  Heterologous Immunity 
 Heterologous immunity is a term that describes either an 
enhancement or delay in viral clearance and subsequent alteration in immune 
pathology associated with an immune host upon infection with a related or 
unrelated pathogen.  Previously, our lab showed that the memory cytotoxic T 
lymphocytes (CTLs) from LCMV-immune mice acutely challenged with either PV 
or VV are able to lyse either the target cells infected with the original LCMV or 
the second challenging virus, suggesting that the established LCMV-specific 
memory populations can be highly cross-reactive (Selin et al., 1994).  
Subsequently, our lab questioned the role these cross-reactive memory CD8 T 
cells play in a heterologous virus challenge.  Our lab found that there was a 
significant reduction in the challenge virus titer (10 to 100 fold reduction) in the 
spleens and abdominal fat pads when LCMV-immune hosts were challenged 
with either PV or VV as compared to naïve mice (Selin et al., 1998).  
Furthermore, adoptive transfer studies showed that both CD4 and CD8 memory 
populations were required for the heterologous immunity in this system (Selin et 

al., 1998).  These studies suggest that cross-reactive T cells might be mediating 
heterologous immunity in the two systems. 
 The LCMV+VV system also demonstrates an interesting aspect of 
heterologous immunity.  The partial protection mediated by the cross-reactive 
expansion of the memory populations can lead to an altered immune pathology.  
LCMV-immune hosts challenged with VV develop severe inflammation in the 
abdominal fat pads that is characterized by white necrotic lesions and T cell 
infiltrates in a pathology known as acute fatty necrosis (AFN) (Selin et al., 1998; 
Yang et al., 1985).  This resembles a similar immune-mediated pathological 
condition in humans known as erythema nodosum, a form of panniculitis.   Thus, 
heterologous immunity is a balance between protection and immune pathology. 
 T cell cross-reactivity has been found between human papillomavirus 
type16 E7 and coronavirus NS2 protein (Nilges et al., 2003).  In addition, cross-
reactive memory CD8 T cells specific to either EBV or hepatitis C virus (HCV) are 
also present in certain human populations that have been previously infected 
with IAV (Clute et al., 2005; Wedemeyer et al., 2001).  Our lab also showed that 
HLA-A2-restricted IAV matrix protein M1-specific T cells generated in bulk culture 

are cross-reactive to an EBV BMLF1 epitope, an early EBV protein required for 
the virus lytic cycle.  In two of the subjects, this cross-reactive expansion in vitro 
accounted for nearly one third of the BMLF1-specific responses.  This finding 
suggests that cross-reactive T cells could contribute to the characteristic lympho-
proliferation that one often witnesses in EBV-associated infectious 
mononucleosis.  However, the two cross-reactive epitopes share 33% in aa 
similarity, demonstrating that in certain cases aa sequence similarity alone could 
not account for this cross-reactivity.  On the other hand, the T cell cross-reactive 
epitopes between IAV (NA 231-239) and HCV (NS3 1073-1081) share a high 
level of aa similarity (7/9 aa similarity) (Wedemeyer et al., 2001).  Ferrari et al 
reported the potential immunological consequence of this T cell cross-reactivity 
when they screened a group of patients with acute HCV infection.  When they 
stimulated the blood samples from each patient using a HCV peptide library to 
examine the cellular immune response, two of the patients with the most severe 
disease known as fuminant hepatitis exhibited extreme dominant responses to 
the HCV NS3 1073-1081 epitope, which is known to be cross-reactive to IAV 
NA231-239 (Urbani et al., 2005).  These strong cross-reactive T cell responses in 

two of the patients correlated with delayed viral clearance and altered immune 
pathology. 
 Dengue virus is a member of the flavivirus family and is prevalent in 
the tropics and causes significant morbidity and mortality in individuals that have 
secondary infections with one of the four heterologous strains (Sangkawibha et 
al., 1984).  Enhancement of antibody-mediated uptake of the virus has been 
proposed to be a plausible mechanism for the high viremia observed in patients 
infected with different serotypes (Morens and Halstead, 1990).  On the other 
hand, it has been hypothesized that?cross-reactive T cells that recognize highly 
similar antigenic epitopes between different strains could be the mediators of 
dengue hemorrhagic fever or dengue shock syndrome.  For example, studies 
have shown that CD8 memory T cells from one serotype infection could be 
activated by another serotype encoding a highly cross-reactive epitope.  In 
addition, activation of these CD8 T cells by the cross-reactive peptides often 
leads to a different cytokine profile compared to the wild type peptide stimulation 
(Imrie et al., 2007; Zivny et al., 1999).  Recently, studies in patients suggested 
that high affinity T cell populations could undergo massive apoptosis (activation-

induced cell death) following a secondary heterologous dengue virus infection 
(Dong et al., 2007; Mongkolsapaya et al., 2003).  In addition, the remaining low 
avidity cross-reactive CD8 T cells have been shown to produce large amounts of 
pro-inflammatory cytokines upon re-stimulation.  In conclusion, all the studies 
suggest that T cell-mediated heterologous immunity is often associated with a 
loss of protective immunity and altered pathology.?
?
C.  Immunodominance Hierarchy and T Cell Cross-Reactivity 
 The phenomenon known as “immunodominance hierarchy” refers to 
the distinct and stable hierarchical patterns in the frequency of antigen-specific 
CD8 T cell responses following an infection.  For example, LCMV infection in B6 
mice always results in the domination by the GP33 and NP396-404 (NP396)-
specific CD8 T cell responses, which together could account for more than 50% 
of the LCMV-specific CD8 cells at peak of the response.  These dominant 
responses are usually accompanied by other epitope-specific CD8 T cell 
responses that are lower in frequency.  For example, LCMV NP205-specific CD8 
T cell responses typically account for roughly 2% to 3% of the total LCMV-
	
specific CD8 responses at day eight post-infection.  On the other hand, infection 
of B6 mice with PV, a new world arenavirus, results in a dominant PV NP38-
specific CD8 T cell response followed by a subdominant PV NP205-specific CD8 
T cell response.  One of the interesting aspects of T cell cross-reactivity between 
LCMV and PV is the alteration of the immunodominance hierarchy by the 
subsequent heterologous viral infection (Brehm et al., 2002).  Infection of either 
LCMV-immune or PV-immune mice with their respective heterologous virus 
results in a massive increase in frequency of the subdominant cross-reactive 
NP205-specific CD8 T cells.  All the experiments so far suggest that multiple 
factors are involved in the generation of immunodominance hierarchy.  For 
example, the antigen expression level, stability of the MHC complex and peptide 
affinity, and TCR repertoire can all play in concert in determining the final 
outcome (Chen et al., 2000).  A finer aspect of the immunodominance hierarchy 
might involve immunodomination of the subdominant clones by the more 
immunodominant clones through mechanisms that are not fully understood.  One 
of the hallmarks of memory T cells is their ability to respond to their cognate 
antigens and proliferate in a rapid fashion without the requirement of co-


stimulatory signals (Veiga-Fernandes et al., 2000).  Therefore, one possibility is 
that the cross-reactive memory T cells have the proliferative advantage and can 
outcompete their naïve counterparts through direct competition with antigen 
presenting cells (APCs).  This would go in line with the observation that 
immunodomination can be removed by expression of the subdominant epitope 
on separate APCs (Roy-Proulx et al., 2001).  Therefore, immunodomination by 
cross-reactive memory T cells could play a role in the alteration of 
immunodominance hierarchy.  In fact, adoptive transfer of carboxyfluorescein 
succinimidyl ester (CFSE)-labeled memory lymphocytes revealed that the cross-
reactive NP205-specific CD8 memory populations preferentially expanded upon 
heterologous virus challenge, indicating their proliferative advantage.  Whether 
these cross-reactive memory T cells directly compete for the interaction with 
antigen presenting cells remain to be studied.  Therefore, the cross-reactive T 
cell response is usually accompanied by the modulation of immunodominance 
hierarchy and could lead to the change in viral clearance and immune pathology. 
 
 
 
 

D.  T Cell Private Specificity 
 In most cases, the specificity and magnitude of cross-reactive T cell 
responses depend on the availability of the TCR repertoire that is present within 
each individual mouse.  This is a term we referred as private TCR repertoire or 
private specificity.  It has been shown that even in genetically identical animals, 
their TCR repertoires are not absolutely identical (Bousso et al., 1998).  This is 
due to the random insertion and deletion of nucleotides of the CDR3 region.  For 
example, the magnitude of the cross-reactive NP205-specific CD8 T cell 
expansion in LCMV-immune mice can be quite varied in each individual mouse 
upon PV challenge (Cornberg et al., 2006).  Another striking example of how 
private TCR repertoire can govern the specificity of the cross-reactive T cell 
responses is seen in LCMV-immune mice following VV challenge.  Adoptive 
transfer experiment using different LCMV-immune donor splenocytes showed 
that either a cross-reactive NP205, GP34, or GP118 would respond following VV 
challenge, depending on the endogenous TCR repertoire of the LCMV-immune 
mouse (Kim et al., 2005).  Therefore, the private specificity of a given antigen-
specific T population can have a dramatic impact on the quality and magnitude of 

the cross-reactive T cell responses and could result in different disease 
outcomes (Nie et al., 2010). 
 
E.  TCR Repertoires and Viral CTL Escape Variants 
 The TCR repertoire is a direct reflection of the diversity of the T cell 
clones that are specific for a given antigenic epitope.  Different antigen-specific T 
cell clones display a preferential usage at the variable region of the TCR beta 
chain (Vβ usage), which can be readily tested by a panel of commercially 
available monoclonal antibodies against different murine Vβs.  For example, 
roughly about 35% of the LCMV-induced CD8 T cell populations use Vβ 8.1 (Lin 
and Welsh, 1998).  However, as many crystal data suggest, the diversity of an 
antigen-specific T cell population lies within the CDR3 regions of the variable 
region of alpha and beta chain of the TCR (Vα and Vβ, respectively) (Bjorkman, 
1997; Garcia et al., 1998; Turner et al., 2006).  Most importantly, the CDR3 
region of the Vβ chain appears to be the most critical determinant of the overall 
TCR repertoire in certain models, since this region plays a crucial role in antigen 
recognition (Ishizuka et al., 2008).  Two of the most commonly employed 

methods for measuring TCR repertoire within antigen-specific clones are TCR 
spectra typing and direct sequencing of the CDR3. 
The reason why some antigenic epitopes induce a diverse TCR repertoire 
while others induce a restricted oligo-clonal TCR repertoire is still not well 
understood.  One study suggests that featureless “vanilla” epitopes tend to select 
a less diverse TCR repertoire with public Vβ usage whereas epitopes with 
prominent features tend to select for a more diverse TCR repertoire (Turner et 
al., 2005).  The overall virus-specific TCR repertoire in LCMV infection appears 
to be stable (Blattman et al., 2000; Lin and Welsh, 1998).  Both reports conclude 
that there is no significant change (skewing) in overall antigen-specific TCR 
repertoire from the acute phase into the memory phase.  However, there are 
certain situations in which antigen-specific TCR repertoire could undergo a clonal 
change.  First of all, several labs observed that under chronic infections, the 
antigen-specific TCR repertoires undergo constant selection (Chen et al., 2001b; 
Day et al., 2007; Lin and Welsh, 1998).  Second of all, the overall TCR repertoire 
also narrows in the naïve T cells that undergo homeostatic proliferation (La Gruta 
et al., 2000), and it can lead to skewing of the Vβ usage and reduction in 

heterologous immunity (Lin et al., 2008).  Finally, we showed that T cell cross-
reactivity between two distantly-related viruses (LCMV and PV) can also lead to 
the narrowing of its cross-reactive TCR repertoires, providing the third scenario 
(Cornberg et al., 2006).  Most of the studies agree that there is a positive 
correlation between diversity of the antigen-specific TCR repertoire and immune 
control of infectious organisms.  In another words, the diversity within the CDR3 
region represented by different CTL clones is critical in recognizing potential 
antigenic variants.  This TCR repertoire diversity is especially important in 
controlling organisms such as RNA viruses with inherently high mutation rates 
(Dockter et al., 1996; Kuntzen et al., 2007).  A good example which illustrates 
this biological principle is the rapid generation of LCMV GP33 escape variant(s) 
in P14 transgenic mice, which express essentially a fixed TCR combination 
specific for LCMV GP33-41 epitope (Pircher et al., 1990).  Thus, a limited TCR 
repertoire specific to an immunodominant epitope dramatically increases the 
odds of generating viral escape variants (Charini et al., 2001; Meyer-Olson et al., 
2004). 

 Viruses and our immune system have co-evolved for millions of 
years.   Viruses have developed a myriad of immune-evasion strategies in order 
to successfully replicate inside a cell and propagate.  For example, a large DNA 
virus such as VV encodes many gene products that can interfere with the innate 
immune system signaling such as interferon alpha/beta (IFN a/b) and IL-18 
pathways (Moss, 2001).  Other viruses that belong to the herpes virus family 
evade immune detection by establishing latency (Cunningham et al., 2006).  For 
RNA viruses such as LCMV that contain relatively small genomes, the viruses 
take advantage of the high mutation rate due to the low fidelity of the RNA-
dependent RNA polymerase (Sevilla and de la Torre, 2006).  As such, 
arenaviruses exist as viral quasispecies that enable them to adapt quickly to 
different selective pressures (Dockter et al., 1996).  For example, an LCMV 
Armstrong strain variant that has the ability to cause persistent infection in mice 
was isolated in the spleens of neonatal mice (Ahmed et al., 1984).  In addition, 
several LCMV CTL epitope escape variants have been selected under either in 
vitro conditions using CD8 T cell lines and in vivo in transgenic mice expressing 
specific Vα and Vβ TCR combinations (Aebischer et al., 1991; Pircher et al., 

1990).  As predicted, all the point mutations occur within the particular CD8 
epitope sequences that were selected against.  These variant CD8 epitopes, also 
referred as altered peptide ligands (APLs), usually differ in aa sequence in 
certain key positions.  Two major mechanisms account for the lack of CD8 T cell 
recognition.  First of all, the switch of an aa residue that contains side chains 
responsible for recognition can result in loss of CTL recognition (Velloso et al., 
2004).  On the other hand, mutation at anchoring residues responsible for the 
binding to the MHC could result in complete loss of recognition since the variant 
APL loses its binding ability (Moskophidis and Zinkernagel, 1995).   
In summary, the overall diversity of the antigen-specific TCR repertoire is 
crucial in recognizing potential CTL escape variants.  T cell cross-reactivity 
between LCMV and PV not only results in alteration of immunodominance 
hierarchy but an extensive narrowing of the cross-reactive TCR repertoire.  
Under such a dominant but narrowed T cell response, we predicted that LCMV 
NP205 epitope escape variants could be selected in vivo.  Finally, isolation of 
LCMV NP205 epitope escape variants could provide further understanding 
regarding the nature of CTL escape variants, T cell cross-reactivity and 

heterologous immunity.  Therefore, the first objective of my thesis work is to 
isolate different kinds of LCMV NP205 escape variants under heterologous virus 
challenge conditions in vivo. 
 
F.  TCR Structure, MHC Recognition, and Antigen Presentation 
 The T cell component of adaptive immunity requires a different way 
to present the foreign peptides.  It is now clear that T cells recognize foreign 
antigens as short stretches of peptides in the context of the major 
histocompatibility complex (MHC) (Bouvier and Wiley, 1994; Rudensky et al., 
1991; Zinkernagel and Doherty, 1974).  For class I MHC presentation (MHC I), all 
the nascent peptides made in cells are cleaved enzymatically by the proteasomal 
machinery in the cytoplasm into small fragments, trans-located into the lumen of 
the endoplasmic reticulum (ER) via the TAP transporter, and bound to class I 
MHC to start the antigen presentation process on the cell surface (Bai and 
Forman, 1997; Shepherd et al., 1993).  The class II (MHC II) antigen 
presentation pathway for CD4 T cells is different and involves acquisition of 
extracellular proteins through the phagosomal compartment.  The proteins are 

proteolytically cleaved in the endosomes into small fragments and presented via 
class II MHC (MHC II) on the cell surface (Deussing et al., 1998).  The majority of 
the T cells in humans and mice express receptors composed of alpha and beta 
subunits.  Both the alpha and beta subunits are composed of variable and 
constants regions (Garboczi et al., 1996).  The variable region of the alpha chain 
consists of re-arranged variable (V), and joining (J) regions.  On the other hand, 
the variable region of the beta chain consists of re-arranged V, diversity (D), and 
J regions. Three CDRs within the variable region of each subunit are important 
for MHC binding and peptide recognition.  The first and second CDRs are 
encoded within the TCR V segment, whereas the CDR3 forms the junctional 
diversity region following the V(D)J recombination (Rowen et al., 1996).  
Therefore, the CDR3 loops are highly diverse in sequence and length and are 
responsible for interaction with bound peptides (Garcia et al., 1998). 
 One of the important questions in modern immunology has been on 
how the mammalian adaptive immune systems discriminate “self” from “non-self”.  
The “clonal selection theory” postulated by Burnet has provided a great frame 
work in explaining how the mammalian immune systems achieve such exquisite 
	
selection (Burnet, 1962).  The T cell selection process takes place in the thymus 
and ensures that each thymocyte express the proper combination of the alpha 
and beta subunits of the TCR in order to recognize peptide-bound MHCs in the 
periphery (Carlyle and Zúñiga-Pflücker, 1998).  Briefly, during the positive 
selection process, each thymocyte must display a correctly recombined TCR 
beta chain paired with a surrogate alpha chain to ensure the proper recognition 
of the self-peptide-MHC (Dudley et al., 1994; Petrie et al., 1993).  This is followed 
by a negative selection process, which ensures that thymocytes with high 
affinities to the self-peptides are eliminated.  Therefore, thymic selection plays an 
important role in the elimination of self-reactive T cells. 
 A number of crystal structure studies on the TCRs and MHC 
complexes have yielded exciting clues about the nature of antigen recognition.  
The current consensus indicates that the Vα and Vβ domains are in close contact 
with the amino and carboxy termini of the peptide, respectively (Ding et al., 1998; 
Reinherz et al., 1999).  In addition, the highly diverse CDR3 loops are generally 
located at the center of the MHC groove for peptide recognition.  It is important to 
note that there could be some exceptions to this generalized observation as 


more TCR-pMHC crystal structures are solved.  Another important feature of 
TCR recognition is its plasticity (Wilson et al., 2004).  Evidence has shown that a 
substantial conformational change could take place upon TCR binding to the 
pMHC, suggesting that a given TCR has the ability to adapt to various terrains on 
the MHC (Garcia et al., 1998). 
 As increasing numbers of cross-reactive TCR:pMHC crystal 
structures are being solved, five different models of TCR cross-reactivity have 
been proposed.  The “induced fit” model highlights the structural adjustment that 
could take place for TCR:pMHC binding while the “differential docking” model 
proposes that difference in docking orientation could play a role in T cell cross-
reactivity (Colf et al., 2007).  The “molecular mimicry” model suggests that a high 
peptide structural similarity can also result in cross-recognition (Harkiolaki et al., 
2009).  On the other hand, the “structural degeneracy” model suggests that an 
epitope that lacks any specific features might actually result in un-expected T cell 
cross-reactivity (Li et al., 2005).  Finally, an interesting model termed “antigen-
dependent tuning of pMHC flexibility” proposes that different peptides can induce 

conformational changes on a MHC to form an important base for TCR cross-
reactivity (Borbulevych et al., 2009). 
 
G.  LCMV: A Prototypical Arenavirus 
  LCMV belongs to the family of arenaviridae, owing to its grain-like 
(sandy) morphology under the electron microscope.  So far, the family of 
arenaviridae consists of 22 members that are divided into two groups based on 
their antigenic properties (Charrel and de Lamballerie, 2003).  The Tacaribe sero 
complex, also known as the New World group, contains viruses that are 
indigenous to the Americas (Emonet et al., 2006).  One example of a New World 
arenavirus is PV.  PV can cause fatality in certain strains of hamsters.  On the 
other hand, the Lassa-lymphocytic choriomeningitis serocomplex are known as 
the Old World arenaviruses that are indigenous to Africa (Emonet et al., 2006).  
Guanarito, Junin, Lassa, Machupo, and Sabia are the 5 members that are able to 
cause hemorrhagic fevers in human (Charrel and de Lamballerie, 2003).  
Specific groups of rodents are the principal hosts of the arenaviruses.  LCMV 
belongs to the Old World arenaviruses but is distributed world wide due to its 

association with Mus musculus.  Occasionally, accidental contact between the 
rodents and humans results in infection.  In fact, LCMV was first isolated from a 
patient who died in the St. Louis encephalitis epidemic in 1933 (Buchmeier et al., 
1980).  The family of Arenaviridae are enveloped, containing two single-stranded 
RNA segments with unique ambisense coding strategy (Buchmeier et al., 1980).  
These two single-stranded RNA segments are appropriately named Large (L) 
and Small (S) segments based on their coding size.  The L segment encodes a 
viral RNA-dependent RNA polymerase and a Z protein that has been suggested 
to interfere with type I interferon induction (Fan et al., 2010; Salvato et al., 1989).  
On the other hand, the S segment contains the viral structural proteins such as 
nucleoprotein (NP) and envelope glycoprotein complex (GPC), which can be 
subdivided into GP1 and GP2 (Riviere et al., 1985).  
LCMV has been a major workhorse in modern immunology.  For example, 
the study of mice congenitally infected with LCMV provided the foundation for 
immune central tolerance mechanisms and thymic selection (Traub, 1939).  The 
rule of TCR-MHC restriction was also discovered in the LCMV system.  Several 
characteristics of the LCMV model have allowed it to become one of the best 

models to study host cellular immunity to viral infections.  First of all, the RNA 
genome of LCMV is relatively small and compact compared to other larger RNA 
and DNA viruses (contains only 4 known gene products).  Therefore, the 
relatively simple genome combined with the fact that LCMV naturally infects mice 
comprises a very robust system.  This allowed tremendous epitope mapping 
efforts to be carried out in the early years and enabled the scientific communities 
to study the interaction between virus and T cell using well defined CD8 and CD4 
epitopes in this system.  Second of all, the non-lytic nature of LCMV infection 
allows scientists to clearly distinguish between viral versus immune-mediated 
pathology (Oldstone and Dixon, 1970).  Third, all the RNA viruses exhibit 
extreme adaptability to the host immune response by virtue of low fidelity RNA 
dependent RNA polymerase activity.  Therefore, the dynamic interplays between 
the virus and the host responses can be greatly appreciated in the LCMV 
system. 
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H.  Host Immune Responses to an Acute LCMV Infection 
 A viral infection represents an intricate balancing act between an 
organism that is trying to hijack the host cell machinery for self-propagation 
verses a host immune surveillance system that is designed to recognize and 
eliminate any foreign organisms.  In an immuno-competent mouse, intra-
peritoneal (i.p.) inoculation of 102 to 105 plaque-forming units (pfu) of LCMV 
induces a very strong antigen-specific CD8 T cell response.  In the initial stage of 
infection, type I interferon is induced within 24 hours as part of the innate 
response and reaches its peak at 72 hours.  At the same time, activated natural 
killer (NK) cells can be found, due to type I interferon induction or target 
recognition (Orange and Biron, 1996; Welsh, 1978).  Although natural killer (NK) 
cells are clearly activated during an acute LCMV infection, there is no indication 
so far that NK cells play a role in innate resistance to LCMV infection (Bukowski 
et al., 1983a; Welsh and Kiessling, 1980).  Instead CTL functions represent a 
major mechanism for controlling of the virus (Kägi et al., 1995).  LCMV is able to 
grow in many tissues, such as blood, liver, spleen, lymph node, thymus, lung, 
kidney and brain (Buchmeier et al., 1980).  The LCMV virus titer peaks at around 

four to five days after infection and the virus becomes undetectable in the blood 
after eight days following infection.  The rapid decline in virus titer correlates with 
the rise of the CTL responses.  The level of the antigen-specific CD8 T cell 
response reaches its peak eight days following an acute LCMV infection.  An 
immunodominance hierarchy can be observed in which different antigen specific 
CD8 T cell responses are arranged in a predictable manner.  Following the peak 
of the CD8 response, more than 90% of highly activated CD8 T cells undergo 
programmed cell death (Razvi et al., 1995).  This immune-silencing state is 
thought to be the major mechanism to transition the immune system back to a 
normalized state. 
Although the total number of CD4 T cells does not increase dramatically, 
the frequency of virus-specific CD4 T cells does increase during an acute LCMV 
infection.  At the peak of the CD4 response, greater than 10% of the CD4 T cells 
that are specific for LCMV peptides produced interferon gamma (IFNγ) by 
intracellular cytokine staining assay (ICS) (Varga and Welsh, 1998). 
Studies have found that non-neutralizing (complement fixing) antibodies 
could be detected as early as four days following an LCMV infection and could 

play a role in controlling virus spread (Geschwender et al., 1976).  Interestingly, 
free neutralizing antibodies that target surface glycoproteins (GP1 and GP2) did 
not seem to be involved in controlling LCMV infection because they remain 
undetectable for long periods of time after infection (Kimmig and Lehmann-
Grube, 1979). 
In summary, an acute LCMV infection in B6 mice is primarily controlled by 
the hosts’ antigen specific CD8 T cell responses.  A stable CD8 
immunodominance hierarchy can be found at the peak of the response eight 
days following infection.  There is no indication of NK cell involvement in 
resistance to LCMV.  However, NK cells are clearly activated upon LCMV 
infection.  Free complement-fixing antibodies can be found early in the LCMV 
infection.  However, neutralizing antibodies, which are thought to be more 
important in controlling the virus titer, do not appear until three to four months 
after infection.  Taken these all together, CTL effector activities are absolutely 
essential in controlling the LCMV infection. 
 
 

I.  CD8 T Cell Response to Persistent LCMV Infection 
 The emergence of an LCMV Armstrong variant called clone 13 in 
Balb/c carrier mice further demonstrated the adaptability of the viruses that 
belong to this arenavirus family (Ahmed and Oldstone, 1988; Ahmed et al., 
1984).  When immunized at a high dose through the intravenous route (i.v.), 
LCMV clone 13 is able to cause a persistent infection in adult mice.  A 
comparison of the RNA genome sequences between the LCMV Armstrong strain 
and the LCMV clone 13 strain has revealed 5 separate single nucleotide 
mutations; two are found in the S RNA segment and three are found in the L 
RNA segment (Salvato et al., 1991).  Two out of five mutations affect the protein 
coding sequence.  The first one is the lysine to glutamine at aa 1079 of the 
polymerase gene.  The second one is the phenylalanine to leucine at amino aa 
260 in the GP1 protein on the viral surface.  Since the persistent phenotype is 
strongly associated with the mutation in GP1, this suggests that a difference in 
binding affinity and viral entry might account for this phenotype (Salvato et al., 
1991).  Oldstone et al confirmed this by first identifying alpha-dystroglycan as the 
cellular ligand for LCMV GP1 binding.  In addition, they found that the binding 

affinity to alpha-dystroglycan of the GP1 from the persistent phenotype was at 
least 1000 fold higher than the acute phenotype (Sevilla et al., 2000). 
 The LCMV Armstrong variant clone 13 provides a useful model to 
study CD8 T cell responses to persistent viral infections.  Initially, a high viral 
load can be detected in various organs such as blood, liver and lung.  Then the 
virus load subsides and is maintained at a low but detectable level.  The virus 
can persist in a host for several months.  Since antigen specific CD8 T cells are 
important in the clearance of LCMV, the failure to clear the virus is due to the 
loss of CD8 T cell effector functions (Zajac et al., 1998).  This CD8 “clonal 
exhaustion” is associated with excess viral replication and high antigen load 
characterized by a progressive loss of different effector cytokines (IL-
2<TNF<IFNγ) (Fuller et al., 2004).  Furthermore, different types of clonal 
exhaustion can be observed between different antigen specific CD8 T cell 
populations.  For example, GP33-specific CD8 T cells become anergized, 
whereas NP396-specific CD8 T cells are completely deleted at the end stage of 
the clonal exhaustion process, as they are unable to be detected by NP396-
specific tetramers (Fuller et al., 2004).  
	
J.  Thesis Objective 
Heterologous immunity is a balance between partial protective immunity 
and immune pathology.  Previously, our lab identified two highly cross-reactive 
NP205-specific CD8 epitopes between LCMV and PV.  In addition, heterologous 
challenge between LCMV and PV resulted in partial protection when compared 
to naïve controls. The overall objective of my thesis work is aimed at delineating 
in greater detail the mechanistic relationship between cross-reactive T cells and 
heterologous immunity using this system.  Most importantly, I will utilize this 
LCMV+PV heterologous challenge system to ask why and how the cross-reactive 
T cells are often associated with immune pathology. 
 
Objective 1.  Isolation of LCMV NP205 escape variants under a dominant 
but narrowed cross-reactive NP205-specific TCR repertoire.  In order to 
examine the relationships of T cell cross-reactivity and heterologous immunity in 
this system, a variant virus that contains either a non-immunogenic form or a 
knockout version of the cross-reactive NP205 epitope would be highly desirable.  
The finding that cross-reactive NP205 populations undergo a selective 


expansion, which results in narrowing of their TCR repertoire following 
heterologous challenge led us to believe that there is a reasonable chance to 
isolate LCMV NP205 epitope escape variants in vivo. 
 
Objective 2.  No formal studies have been done to establish the direct link 
between the cross-reactive NP205-specific CD8 populations and heterologous 
immunity between LCMV and PV.  In addition, some reports suggest bystander T 
cell activation, whereby T cells are activated by the cytokine milieu in a MHC-
independent manner, as a potential mechanism for heterologous immunity.  To 
find out whether cross-reactive NP205-specific CD8 T cells are mediators of 
heterologous immunity between LCMV and PV, I will compare the level of 
heterologous immunity between LCMV WT and LCMV NP-V207A-immune 
animals following PV challenge.  We hypothesize that if the cross-reactive 
NP205-specific CD8 T cells were mediators of heterologous immunity in this 
model, we would observe a significant loss of heterologous immunity in the 
LCMV NP-V207A-immunized mice challenged with PV. 
 

Objective 3.  Our data showed that the establishment of a large cross-reactive 
NP205-specific CD8 T cell populations in mice that received PV and LCMV 
immunization in a sequential manner could often cause more harm than good 
when the hosts received PV as a final challenge.  These mice developed a high 
incidence of AFN.  Therefore, we questioned the role the cross-reactive NP205-
specific CD8 T cells may play in immune pathogenesis.  I will compare the 
incidence of AFN between the (PV+LCMV WT) and (PV+LCMV NP-V207A) 
double immune mice following PV re-challenge.  If our hypothesis is correct, we 
should expect a significant lower incidence of AFN in the (PV+LCMV NP-V207A) 
double immune mice challenged with PV.  This finding could have important 
implications for the tailoring of the immune response in future vaccine designs. 
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Chapter II 
Material and Methods 
 
A.  Mice 
C57BL/6 (B6, H2-Kb) male mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME).  B6.SJL-ptprca (it.1) congenic male mice (Ly5.1) 
were purchased from Taconic Labs (Germantown, N.Y).  All the mice were used 
at 2-12 months of age and maintained under specific pathogen-free conditions at 
UMMS.  All animal work was reviewed and approved by the UMMS IACUC 
committee. 
 
B.  Virus stocks and infection protocol 
LCMV (Armstrong strain and clone 13), LCMV NP-V207A, in vitro rescued 
LCMV variants (r/LCMV WT and r/V207A), and PV (AN3739 strain) were 
propagated in BHK-21 cells as described (Selin et al., 1994).  To avoid immune 
responses generated to bovine serum following sequential infections, PV was 
purified by sucrose density gradient ultra-centrifugation and diluted in HBSS 
before immunization (Selin et al., 1998). 

For primary infections, mice were immunized i.p. with 5x104 plaque 
forming units (pfu) of LCMV and 2x107 pfu of purified PV.  Mice were considered 
immune 6 weeks after immunization.  For homologous challenge, PV-immune 
mice were challenged i.p. with 2x107 pfu of purified PV.  For heterologous 
challenge, PV-immune mice were challenged i.p. with 5x104 pfu of LCMV clone 
13.  LCMV-immune mice were challenged i.p. with 2x107 pfu of purified PV.  For 
generation of (PV+LCMV WT) and (PV+LCMV NP-V207A) double immune mice, 
PV-immune animals were challenged i.p. with 1x106 pfu of LCMV WT or LCMV 
NP-V207A variant. 
 
C.  Isolation of the LCMV CTL escape variant 
For isolation of an epitope escape variant, PV-immune mice were 
inoculated with 2x105 pfu of LCMV clone 13 i.v., and virus was isolated from the 
kidney 8 months later.  LCMV plaques were excised and used to infect MC57G 
cell monolayers in 12-well plates.  After 48 hours total cellular RNA was isolated, 
reverse transcribed using a poly-T primer, and the NP205 region of the cDNA 
was PCR amplified using 0.3μM each of flanking primers 5’-GGTCCTCGC-
TGTTGCTTGGCTTGA-3’ and 5’-TGGGGAGGCTCAGTGCAGAAGAAC-3’, using 

pfx polymerase from invitrogen corporation (Carlsbad, CA).  The PCR conditions 
were: (a) 94°C for 2 minutes; (b) 94°C for 15 seconds, 58°C for 30 seconds, and 
72°C for 60 seconds (repeated 30 times); (c) 72°C for 60 seconds.  DNA 
sequencing was done at the UMMS sequencing facility with custom primers (5 
pmol/μl), 5’-CACCAAGACTAAAGTTATAGCCAG-3’ and 5’-
AGGGTGCAAGTGGTGTGGTAAGAG-3’.  The following murine β -actin primers 
were used: forward 5’-CGAGGCCCAGAGCAAGAGAG-3’; reverse 5’-
CGGTTGGCCTTAGGGTTCAG-3’. 
 
D.  MHC-Ig dimer 
Soluble dimeric mouse H2-Kb-Ig fusion proteins (MHC-Ig dimer) were 
purchased from BD Bioscience (San Diego, CA).  The LCMV WT NP205-212 
and LCMV NP205-212 (V-A) peptides (1mg/ml) were incubated with the MHC-Ig 
dimer at an 800 to 1 molar ratio and recombinant human beta-2 micro-globulin 
(0.15μg/μg of dimer) from BD Bioscience at 4°C for 4 days to allow passive 
loading of the peptide.  The final products were used for surface staining assays. 
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E.  Synthetic peptides 
LCMV peptides GP33-41 (KAVYNFATC), GP92-101 (CSANNSHHYI), 
GP118-125 (ISHNFCNL), GP276-286 (SGVENPGGYCL), NP396-404 
(FQPQNGQFI), NP205-212 (YTVKYPNL), NP205-212 (V-A) (YTAKYPNL), 
L1878-1885 (GPFQSFVS), PV NP38-45 (SALDFHKV) and PV NP205-212 
(YTVKFPNM) synthetic peptides were purchased from BioSource International or 
21st Century Biochemicals with 90% purity. 
LCMV peptides L156-163 (ANFKFRDL), L338-346 (RQLLNLDVL), L349-
357 (SSLIKQSKF), L455-463 (FMKIGAHPI), L689-697 (KFMLNVSYL), L775-
782 (SSFNNGTL), L1428-1435 (NSIQRRTL), L1878-1885 (GPFQSFVS), and 
L2062-2069 (RSIDFERV) were kindly provided by Dr. Alessandro Sette from the 
La Jolla Institute for Allergy and Immunology (Kotturi et al., 2007). 
 
F.  Peptide/MHC stabilization assay 
TAP-1 deficient RMA-S cells (Townsend et al., 1989) were seeded into 96-
well U-bottom plates at 5x105 cells per well.  Following an incubation in a 5% 
CO2 incubator at 27°C for 4 hours, NP205 peptides were added at different 
concentrations and incubated overnight.  The cells were then stained with mAb to 

H2-Kb (clone AF6 88.5) conjugated with PE (BD Bioscience) and analyzed by 
FACS. 
 
G.  Functional avidity assay 
Splenocytes (1x106 cells/well) were placed in a 96-well plate with 0.2μl of 
Golgi Plug (BD Bioscience) and human recombinant IL-2 (10U/ml) (BD 
Bioscience).  10x serial dilutions of a given peptide were made (starting at 5μM) 
and added to individual wells.  The plate was incubated at 37°C in 5% CO2 for 5 
hours followed by surface staining and ICS.  A peptide titration curve was 
generated as % maximum IFNγ release using the frequency of IFNγ+, CD8α+ T 
cells stimulated with the highest concentration of peptide as 100%. 
 
H.  Acute fatty necrosis scores 
  The severity of AFN was scored based on the guidelines from a previous 
publication (Selin et al., 1998).  (1-2) very mild to mild disease with a few white 
necrotic spots on one or both lower abdominal fat pads; (3-4) mildly moderate 
and moderate with larger patches of necrosis of the lower abdominal fat pads 
and extension into the upper left quadrant fat pad around the spleen; (5-6) 

moderately severe to severe with very extensive large patches of necrosis on the 
lower abdominal fat pads and spotty fatty necrosis throughout omental fat pads 
as well as the splenic fat pad; (7) very severe disease with such severe fatty 
necrosis that the organs are adherent to each other. 
 
I.  Plaque assay 
Organs were harvested and homogenized with a tissue homogenizer in 1 
to 2 ml of tissue culture medium.  The supernatants were collected and stored in 
an -80 °C freezer.  ATCC Vero cells (2x105 cells/well) were used to titrate LCMV 
and PV (Bukowski et al., 1983b). The plates were stained with neutral red at 
either 3 (LCMV) or 4 (PV) days after the infection.  The plaques were counted 24 
hours after.  The pfu was expressed as Log10 pfu/ml. 
 
J.  Isolation of lymphocytes from fat pad tissue 
The infiltrating leukocytes in the fat pads were isolated by mincing and 
digesting with collagenase B (200 mg/ml) in MEM plus 4% BSA for 1 hour at 37° 
C, and then separated over Lympholyte®-M from Cederlane Laboratory 
(Burlington, ON).  A standard peptide stimulation protocol is performed followed 
by surface staining and ICS. 

 
K.  Intracellular cytokine staining (ICS) 
Leukocytes from spleens, blood and abdominal fat pads (1x106 cells/well) 
were stimulated with either medium or 1μM peptides containing 0.2μl of 
GolgiPlug and human recombinant IL-2 (BD Pharmingen) at 37°C for 5 hours.  
Intracellular cytokine staining was performed using a cytofix/cytoperm kit from BD 
Bioscience.  Intracellular cytokine-producing cells were detected with 
allophycocyanin (APC)-conjugated anti-mouse IFNγ monoclonal antibodies 
(1:1000) (XMG1.2) and phycoerythrin-Cy7 (PE-Cy7)-conjugated anti-mouse 
TNFα (1:200) (MP6-XT22). 
 
L.  Cell Surface and MHC-Ig dimer staining by flow cytometry 
All the surface antibodies were used at a 1:200 dilution per well.  Single-
cell suspensions of splenocytes or blood lymphocytes were first incubated with 
anti-mouse CD16/CD32 Fc-block antibody (1μl/well) for 15 minutes on ice.  
Subsequently a cell surface staining procedure was performed using PerCP-
Cy5.5 anti-mouse CD8α (clone 53-6.7) and FITC anti-mouse CD44 (clone IM7).  
The samples were incubated on ice for 20 minutes. 
	
For MHC-Ig dimer studies, the splenocytes were first blocked with the Fc-
block (1μl/well) for 15 minutes on ice.  Subsequently, different amounts of MHC-
Ig dimers loaded with different LCMV NP205 peptides were added to the 
samples and incubated for 1 hour on ice.  This was then followed by the regular 
surface staining protocol. 
 
M.  Generation of in vitro rescued LCMV variant viruses 
The generation of the rescued(r) recombinant LCMV (r/LCMV) in vitro has 
been reported (Sanchez and de la Torre, 2006).  Briefly, the cDNAs derived from 
either the S and L segments of LCMV Armstrong strain were inserted separately 
into expression plasmids with a T7 promoter.  In addition, 3 other plasmids were 
required.  A plasmid expressing T7 polymerase, along with two other plasmids 
expressing either LCMV cis and trans activating factors were required.  Finally, 
all five plasmids were transfected into BHK-21 cells and r/LCMV could be 
detected in the tissue culture supernatant. 
The nucleotide sequence that contained the original point mutation was 
sent to our collaborators at Scripps Research Institute in La Jolla.  The cloning 
and rescue of the recombinant LCMV NP-V207A (r/V207A) was done by Andrew 


Trees, a student of the Immunology Summer Program, directed by Sebastien 
Emonet in Dr. Juan Carlos de la Torre’s laboratory.  In addition, r/LCMV 
containing different versions of the anchoring residue mutation in the LCMV 
NP205 epitope were also generated. 
 
N.  Adoptive transfer experiments 
LCMV-immune splenocytes (2x107) expressing the Ly5.2 congenic marker 
were CFSE-labeled and injected i.v. (200ul) into congenic C57BL/6 mice (Ly5.1).  
One day after, the mice were challenged i.p. with 2x107 pfu of PV.  The spleens 
were harvested 8 days following infection and stimulated with different peptides 
for 5 hours.  Standard surface staining and ICS were preformed. 
 
O.  Peptide:MHC crystal structure 
The crystal structures of the LCMV and PV NP205 peptides:H2-Kb 
complexes were generated by Carole Guillonneau and Stephanie Gras under the 
guidance of Stephen Turner (Department of Microbiology and Immunology, The 
University of Melbourne, Parkville, Australia) and Jamie Rossjohn (The Protein 
Crystallography Unit, Department of Biochemistry and Molecular Biology, School 
of Biomedical Sciences, Monash University, Victoria, Australia), respectively. 

 
P.  Statistical analysis 
Statistical analysis was performed using GraphPad Prism™ software 
(5.0b).  Comparisons between two groups were performed using the unpaired 
Student’s t test (2-tailed).  Comparisons between more than two groups were 
performed using one way ANOVA analysis (2-tailed).  Pearson’s correlation test 
was used to measure the correlation between two independent variables.  P 
values less than 0.05 were considered statistically significant. 
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CHAPTER III 
Isolation of A LCMV NP205 Epitope Escape Variant Under 
Conditions Driven By Heterologous Immunity 
 
Previously, our lab showed that heterologous challenge between LCMV 
and PV could result in a selective expansion of the cross-reactive NP205-specific 
CD8 T cells.  These cross-reactive NP205-specific CD8 T cells are oligo-clonal in 
nature.  Since T cell oligo-clonality (narrowed TCR repertoire) had been 
correlated with an increase in incidence of viral escape in other systems (Kalams 
et al., 1994), we questioned if LCMV NP205 CTL escape variants could be 
generated in vivo as one of the immunological consequences following a 
heterologous challenge in this particular system.  Based on all the previous 
knowledge that we learned from this heterologous system, I believed that there 
was a reasonable chance of success.  First of all, the cross-reactive NP205-
specific CD8 T cell responses dominate the immune response and dramatically 
change the immunodominance hierarchy following a heterologous challenge 
(Brehm et al., 2002).  Second, there was a significant narrowing (skewing) in the 
cross-reactive NP205-specific CD8 T cell repertoire in vivo following a 
heterologous challenge (Cornberg et al., 2006).  Finally, due to the low fidelity in 

RNA dependent RNA polymerase, LCMV exists as quasispecies and is highly 
adaptable in nature (Sevilla and de la Torre, 2006).  In fact, different LCMV CTL 
escape variants have been generated under either in vitro or in vivo conditions 
(Lewicki et al., 1995). 
The first step to isolate LCMV NP205 CTL variants in vivo was to 
challenge PV-immune mice with LCMV clone 13 (LCMV WT) and wait for the 
onset of viral persistence (Fig 3.1).  LCMV clone 13 is a genetic variant of LCMV 
Armstrong strain.  In contrast to the LCMV Armstrong strain, the LCMV clone 13 
is able to establish persistent infections when inoculated at high dose i.v. (2x106 
pfu/mouse).  Since viral fitness, pressure of the CTL selection, and many other 
factors all play a role in determining the outcome of the viral CTL escape 
selection, a LCMV clone 13 infection that causes a persistent infection is 
important.  This prolonged viral replication could dramatically increase the odds 
of generating LCMV NP205 CTL escape variants in vivo.  Following a period of 
viral persistence, peripheral organs were harvested at different time points for 
viral plaque assay.  Subsequently, individual LCMV plaques were picked and 
screened for point mutations within the LCMV NP205 epitope region.  Briefly, two 
	
sets of primers specifically designed to amplify the LCMV NP205 region were 
used for PCR amplification and subsequent sequencing reactions.  All the LCMV 
CTL escape variants previously isolated either in vitro or in vivo bear point 
mutation(s) within their respectively selected epitopes, indicating the direct 
relationship between the location of the mutation and the CTL selective pressure 
(Aebischer et al., 1991; Pircher et al., 1990).  Therefore, I anticipated that LCMV 
NP205 CTL escape variants would contain mutation(s) in the LCMV NP205 
epitope. 
	
 
PV
-Im
m
un
e 
PV
-
Pe
rs
is
te
nt
 d
os
e 
LC
M
V 
C
lo
ne
 1
3 
D
o
m
in
a
tio
n
 
o
f 
cr
o
ss
-r
e
a
ct
iv
e
 
N
P
2
0
5
-s
p
e
ci
fic
 
C
D
8
 
T
 
ce
lls
 
w
ith
 n
a
rr
o
w
e
d
 T
C
R
 r
e
p
e
rt
o
ir
e
 
in
 t
h
e
 p
re
se
n
ce
 o
f 
h
ig
h
 v
ir
a
l 
a
n
ti
g
e
n
 l
o
a
d
 
N
P3
8 
N
P2
05
 
N
P3
8 
N
P2
05
 
G
P3
3 
N
P3
96
 
S
e
le
ct
io
n
 o
f 
L
C
M
V
 
N
P
2
0
5
-2
1
2
 C
T
L
 
e
sc
a
p
e
 v
a
ri
a
n
ts
 
W
T
 
V
 
V
 
V
 
V
 
V
 
F
ig
u
re
 3
.1
  
S
ch
e
m
a
tic
s 
o
n
 in
 v
iv
o 
g
e
n
e
ra
tio
n
 o
f 
L
C
M
V
 N
P
2
0
5
-2
1
2
 C
T
L
 e
sc
a
p
e
 v
a
ri
a
n
ts
. 
 
V
 
	
 
A.  Specific PCR amplification and sequencing of the LCMV NP205 epitope 
region 
An in vitro viral culture system was set up to screen all the potential LCMV 
NP205 CTL escape variants.  The LCMV Armstrong containing the wild type 
LCMV NP205 sequence was used as a positive control.  Briefly, the MC57G cell 
line derived from B6 mice was infected with different LCMV plaque isolates.  
After 48 hours, total messenger RNA was isolated and reverse-transcribed into 
cDNA.  The region that spanned the LCMV NP205 epitope was amplified by 
PCR.  Subsequently, the PCR products were purified and sequenced with a 
different set of primers.  Figure 3.2A shows the specific amplification of the 
region that encompasses the LCMV NP205 epitope in MC57G cell lines infected 
with LCMV Armstrong (lane 1).  The size of the PCR product (~548bp) confirms 
the specificity of the primer pair used in the experiment.  The internal controls 
using either commercially supplied RNA (Fig 3.2A, lane 7) or murine beta-actin 
controls indicate that there are no confounding factors in the reaction (Figure 
3.2B).  Finally, sequencing of the PCR product in either direction (forward and 
reverse) reveals unequivocally the wild type LCMV NP205 sequence in both 
	
nucleotide level and aa levels (YTVKYPNL) (Figure 3.3).  In addition, the 
sequence data matched specifically to the NP205 region of the LCMV 
nucleoprotein using the NIH nucleotide blast search program (data not shown).  
Therefore, we have established an in vitro system for screening of potential point 
mutations within the LCMV NP205 epitope region. 
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B.  The LCMV NP-V207A escape variant contains a variant NP205 epitope 
sequence that resembles the Lassa virus sequence in nature 
 In a group of PV-immune mice challenged with LCMV clone 13 (N=4), a 
LCMV NP205 epitope escape variant (LCMV NP-V207A) was isolated from the 
kidney of a test animal eight months after infection.  The kidney could possibly 
represent the site of LCMV persistence, because they were the only organs that 
still harbored the virus (spleen and brain tissues). A single point mutation was 
detected within the third aa codon sequence (GTC to GCC) of the LCMV NP205 
epitope.  The frequency of the LCMV NP-V207A variant virus in the kidney of this 
particular host is approximately 20%, because one out of five viral clones 
contained the point mutation (figure 3.4).  Moreover, no sequence mutation(s) 
was detected within the region encompassing the LCMV NP205 epitope from the 
rest of the animals (0/15).  Finally, no additional mutation(s) were found in the 
remaining stretch of sequences that encompass the LCMV NP205 epitope 
(~250bp sequence) in the LCMV NP-V207A variant. This single point mutation 
predicts a change of the original valine (V) to alanine (A) at the third position of 
the LCMV NP205 epitope (Table 3.1).  Based on the putative K
b binding motif 
	
published by several labs, this is a non-anchoring aa residue mutation.  However, 
the third aa residue in Kb has been indicated as an auxiliary anchoring residue, 
suggesting that it is also an important residue for binding and recognition 
(Hudrisier et al., 1997).  Finally, the highly conserved nature of the LCMV NP205 
epitope sequences from both the Old World and New World arenaviruses reveal 
an interesting aspect of this mutation (Table3.1) 
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Comparison of the majority of NP205 sequences indicated that only three 
positions are subjected to variations among the different arenaviruses.  Two of 
them are the putative anchoring residues at positions five and eight.  The last 
variable is at position three, which is the auxiliary anchoring residue.  
Interestingly, the only variation for the third position so far is between either a 
valine or an alanine.  While all the New World arenaviruses contain valine at the 
third position, the Old World arenaviruses contain either a valine (LCMV) or an 
alanine (Lassa virus and Mopeia virus).  Thus, this V to A mutation in the LCMV 
NP-V207A escape variant reflects the specificity and delicate balance between 
viral fitness and host responses.  Interestingly, the mutated LCMV NP205 epitope 
sequence now resembles the Lassa virus NP205 sequence in nature. 
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
C.  The variant NP205 epitope stabilizes Kb in vitro but elicits a significantly 
lower antigen-specific CD8 T cell response at physiological concentrations 
 Based on the putative sequence of the NP205 (V-A) epitope, the epitope 
should be able to bind to Kb.  I set up an in vitro MHC stabilization assay to 
address this question.  Briefly, TAP-deficient RMA-S cells that have been shown 
to maintain a very low class I MHC expression on their surface due to a defect in 
peptide transport into the ER were used for the assay (Ljunggren et al., 1990).  
When peptide fragments that contain the putative binding motifs are added 
exogenously, an increase in class I MHC expression on the cell surface can be 
seen.  Therefore, I compared the ability of the LCMV NP205 (YTVKYPNL) and 
the LCMV NP205 (V-A) (YTAKYPNL) peptides to stabilize Kb in vitro.  Both 
LCMV NP205 and LCMV NP205 (V-A) peptides are able to stabilize Kb at 100μM 
concentration, as shown by a significant increase in the mean fluorescence 
intensity (MFI~40.0) for antibody against Kb (Figure 3.5A).  The un-pulsed RMA-
S cells indicate the basal level of antibody staining (MFI~10.0) (Figure 3.5A).  
Finally, the peptide titration curves suggest that both wild type and LCMV NP205 
(V-A) peptides bind Kb with similar affinity and kinetics (Figure 3.5B).  Overall, 
these data suggest that the LCMV NP205 (V-A) peptide can bind to Kb in a 


similar manner as the wild-type LCMV NP205 peptide, and can probably be 
presented in vivo. 


 
  
0
 
5
 
1
0
 
1
5
 
2
0
 
2
5
 
3
0
 
3
5
 
4
0
 
4
5
 
1
0
0
u
M
 
1
0
u
M
 
1
u
M
 
.1
u
M
 
K
b
 Mean Flourescence Intensity 
L
C
M
V
 N
P
2
0
5
-2
1
2
 
L
C
M
V
 N
P
2
0
5
-2
1
2
 (
V
-A
) 
A 
B
 
K
b
 
L
C
M
V
 N
P
2
0
5
-2
1
2
 
L
C
M
V
 N
P
2
0
5
-2
1
2
 (
V
-A
) 
N
o
 p
e
p
tid
e
 
F
ig
u
re
 3
.5
  
T
h
e
 L
C
M
V
 N
P
2
0
5
-2
1
2
 (
V
-A
) 
p
e
p
tid
e
 m
a
in
ta
in
s 
th
e
 a
b
ili
ty
 t
o
 s
ta
b
ili
ze
 K
b
 in
 v
itr
o.
 
R
M
A
-S
 
ce
lls
 
w
e
re
 
in
cu
b
a
te
d
 
w
ith
 
d
iff
e
re
n
t 
co
n
ce
n
tr
a
tio
n
s 
o
f 
e
ith
e
r 
L
C
M
V
 
N
P
2
0
5
-2
1
2
 
o
r 
L
C
M
V
 N
P
2
0
5
-2
1
2
 (
V
-A
) 
p
e
p
tid
e
 o
ve
rn
ig
h
t.
  
C
e
ll 
su
rf
a
ce
 s
ta
in
in
g
 w
a
s 
p
e
rf
o
rm
e
d
 b
y 
u
si
n
g
 a
 
m
o
n
o
cl
o
n
a
l 
a
n
tib
o
d
y 
a
g
a
in
st
 K
b
. 
 (
A
) 
re
p
re
se
n
ts
 t
h
e
 K
b
 e
xp
re
ss
io
n
 o
n
 t
h
e
 R
M
A
-S
 c
e
lls
 
In
cu
b
a
te
d
 
w
ith
 
1
0
0
μ
M
 
o
f 
in
d
ic
a
te
d
 
p
e
p
tid
e
s.
 
 
(B
) 
re
p
re
se
n
ts
 
th
e
 
a
ve
ra
g
e
 
tit
ra
tio
n
 
cu
rv
e
 
b
e
tw
e
e
n
 t
h
e
 t
w
o
 i
n
d
ic
a
te
d
 p
e
p
tid
e
s 
u
si
n
g
 d
u
p
lic
a
te
 s
a
m
p
le
s.
 
 T
h
e
se
 a
re
 r
e
p
re
se
n
ta
tiv
e
 o
f 
tw
o
 in
d
e
p
e
n
d
e
n
t 
e
xp
e
ri
m
e
n
ts
. 
1
0
0
μ
M
 


Next, I wanted to know how efficient the LCMV NP205 (V-A) peptide was at 
stimulating either LCMV or LCMV+PV effector T cell responses.  Both LCMV 
NP205 and LCMV NP205 (V-A) peptides are able to stimulate NP205-specific 
CD8 T cells under a 5000 nM saturating condition (Figure 3.6).  However, at a 
concentration that mimics physiological conditions (10,000 fold lower), a 
significant difference in IFNγ production between the LCMV NP205 and NP205 
(V-A) peptide-stimulated groups was observed.  In figure 3.6B, a significant 
reduction in the antigen-specific CD8 T cell response (~80% reduction) to the 
LCMV NP205 (V-A) peptide can be seen using the PV+LCMV WT T cell effectors 
at peptide concentration of 0.5nM (p=0.0045).  In addition, a similar reduction in 
IFNγ production can be seen when using the LCMV WT effectors (Figure 3.6A).  
However, this difference is not as great as the one using the PV+LCMV WT 
effectors (Figure 3.6B).  Since the mutation within the LCMV NP205 epitope was 
selected by a very small group of cross-reactive NP205-specific CD8 T cells, it is 
possible that the primary LCMV NP205-specific CD8 T cell response that 
contains a more diverse repertoire is able to recognize this variant epitope more 
efficiently. 

	
 Overall, these data suggest that that the variant NP205 peptide is able to 
stabilize Kb in vitro and possibly be presented in vivo.  However, there is a 
significant reduction in the ability of the LCMV NP205 (V-A) peptide to stimulate 
LCMV or PV+LCMV WT CD8 effector T cells at lower peptide concentrations.  
This suggests that the LCMV NP205 (V-A) peptide could be much less 
immunogenic in nature.  
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D.  Infection of B6 mice with the LCMV NP-V207A variant results in a 
significantly diminished cross-reactive NP205-specific CD8 T cell response 
 To determine the immunogenicity of the LCMV NP205 (V-A) peptide in 
vivo, we infected B6 mice with a low dose (5x104 pfu) of either LCMV WT or 
LCMV NP-V207A viruses and analyzed their acute responses eight days after 
infection.  I found that mice immunized with the LCMV NP-V207A variant 
displayed a significantly diminished cross-reactive response (LCMV NP205, 
LCMV NP205 V-A, and PV NP205) as compared to the mice infected with LCMV 
WT (Figure 3.7).  In contrast to a significant reduction in cross-reactive NP205-
specific CD8 T cell responses in the LCMV NP-V207A-infected animals, all the 
other LCMV specific T cell responses were comparable in mice infected with 
either virus (Figure 3.7).  
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Since only a small percentage of CD8 T cells (0.7%) responded to the LCMV 
NP205 (V-A) peptide stimulation in the LCMV NP-V207A-infected mice (Figure 
3.7B), this result suggests that the point mutation has rendered the LCMV NP205 
(V-A) epitope much less immunogenic in nature.  This is consistent with our 
hypothesis that a dominant cross-reactive NP205-specific CD8 T cell response 
would select an LCMV variant that expresses a variant epitope that might evade 
such an immune response. Similarly, PV-immune mice challenged with the 
LCMV NP-V207A virus exhibit very little increase in the frequency of the cross-
reactive NP205-specific CD8 T cell responses eight days after infection as 
compared to PV-immune mice challenged with LCMV WT (Figure 3.8, 1% vs. 
18% of the CD8 response, respectively).  These data suggest that the NP205 
variant epitope is less immunogenic and results in very little cross-reactive 
expansion upon PV challenge.  However, it is also possible that the LCMV 
NP205 (V-A) epitope could induce a very different T cell functionality that we 
could not pick up using a standard ICS assay.  Studies using MHC-Ig dimers 
loaded with the LCMV NP205 (V-A) peptide are described in the second part of 
chapter four to address this particular question. 

 
E.  Both the LCMV WT and LCMV NP-V207A variants display similar 
replication kinetics in vivo and maintain the ability to clonally exhaust T 
cells 
 Next, we compared the replication kinetics between the LCMV WT and the 
LCMV NP-V207A variant viruses.  When mice were infected with a low dose (5x 
104 pfu) of either LCMV WT or LCMV NP-V207A virus, no significant difference in 
virus titer could be detected between the two groups in all the organs tested 
(abdominal fat pad and kidney) six days after infection (Figure 3.9).  Most 
importantly, both the LCMV WT and LCMV NP-V207A variant viruses are rapidly 
cleared by day nine post-infection and remain undetectable in all the major 
organs tested in the immune hosts (Figure 3.9) 

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With the notable exception that a very small LCMV NP205-specific CD8 T cell 
response was detected in LCMV NP-V207A-infected mice, the overall magnitude 
as well as the kinetics of the antigen-specific CD8 T cell responses was very 
similar in mice infected with either LCMV WT or LCMV NP-V207A (Figure 3.10).  
For example, the overall antigen-specific CD8 T cell responses peaks at around 
day nine post-infection and undergoes a contraction phase to reach the immune 
stage in mice infected with either virus (Figure 3.10).  Therefore, the point 
mutation in the subdominant NP205 epitope did not result in any noticeable 
perturbation in either viral replication or T cell activation kinetics in the LCMV NP-
V207A-immune hosts. 
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Since the LCMV NP-V207A was isolated in the LCMV clone 13 
background, we asked whether the variant still retains the LCMV clone 13 
phenotype in vivo.  Like the LCMV clone 13, the LCMV NP-V207A variant is able 
to induce T cell clonal exhaustion when inoculated at high dose (2x106 pfu) i.v. 
(Figure 3.11).  Similar to the original report (Fuller et al., 2004), two of the major 
immunodominant T cell responses become either anergic (GP33) or deleted 
(NP396) in mice infected with high dose variant (Figure 3.11).  Again, these data 
point out that specifically the pressure of the cross-reactive NP205 CTL selection 
drove the point mutation in the LCMV NP-V207A variant and that it probably 
imparted a minimal effect on other sequences. 
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Chapter Summary 
 
T cell cross-reactivity between two distantly related arenaviruses, LCMV 
and PV, results in a dominant expansion of cross-reactive subdominant NP205-
specific CD8 T cells upon heterologous challenge, and, importantly, a significant 
narrowing of the cross-reactive NP205-specific CD8 T cell repertoire was 
observed (Cornberg et al., 2006).  We predicted that NP205 CTL escape variants 
could be generated as the result of a dominant but narrowed cross-reactive 
NP205-specific CD8 T cell responses upon heterologous challenge. 
 Indeed, a LCMV NP-V207A CTL escape variant was isolated in a 
PV-immune mouse challenged with the heterologous LCMV.  A point mutation 
was detected within the nucleotide sequence encoding the LCMV NP205 
epitope, resulting in a switch of valine to alanine at the non-anchoring third aa 
residue (Figure 3.4).  The resulting LCMV variant NP205 sequence resembles 
Lassa virus sequences in nature (Table 3.1).  Furthermore, the LCMV NP205 (V-
A) peptide displays the ability to stabilize Kb as efficiently as the wild type NP205 
peptide, but is significantly less efficient at stimulating LCMV NP205-specific T 

cell responses at lower physiological conditions in vitro (Figure 3.5 & 3.6).  Most 
importantly, this LCMV NP205 (V-A) epitope seems to be much less 
immunogenic in vivo, as mice infected with the LCMV NP-V207A variant virus 
display a greatly diminished NP205-specific CD8 T cell responses (Figure 3.7 & 
3.8).  However, the LCMV NP-V207A variant virus displays similar replication 
kinetics and antigen-specific T cell responses to other major LCMV epitopes in 
vivo (Figure 3.9 & 3.10).  In keeping with the original clone 13 background, the 
LCMV NP-V207A variant virus maintains its ability to induce T cell clonal 
exhaustion in its host in vivo (Figure 3.11).  Furthermore, no additional 
mutation(s) were found in the remaining stretch of sequences that encompass 
the LCMV NP205 epitope (~250bp sequence) in the LCMV NP-V207A variant.  
This suggests that the point mutation in the NP205 epitope was selected by a 
dominant cross-reactive NP205-specific CD8 T cells upon heterologous 
challenge and this point mutation did not seem to affect the general replication 
characteristics of the LCMV clone 13 strain.  Finally, the data presented above 
suggest that the single point mutation within the LCMV NP205 epitope results in 
a significant reduction in its immunogenicity. 

It was interesting to find that a single amino acid switch (V-A) could result 
in such a dramatic loss in immunogenicity (Fig 3.7).  One recent report has 
shown a similar finding in which a mutation in the original epitope resulted in loss 
of immunogenicity.  It has been suggested that virus utilized this strategy to 
exploit “hole” in hosts’ T cell repertoire (Wölfl et al., 2008).  This would imply that 
the mutated epitope could possibly resemble self peptides/antigens of the host 
so that most of the T cells that are able to recognize this variant epitope are 
deleted during negative selection in the thymus. 
 
 
 
 
 
 
 
 
 
 
 

Chapter IV 
T Cell Cross-Reactivity and Heterologous Immunity 
 
 
Part I 
Previous studies from our lab showed that heterologous immunity 
between different viruses and bacteria is dependent on the sequence and route 
of challenge (Chen et al., 2001a; Mathurin et al., 2009).  For example, T cell-
mediated heterologous immunity can be demonstrated between LCMV and PV in 
a bi-directional manner, as secondary challenge with the heterologous virus 
results in partial protective immunity without apparent immune-associated 
pathology (Selin et al., 1998).  One of the key questions regarding T cell cross-
reactivity and heterologous immunity has been whether the cross-reactive 
memory T cells are directly responsible for the heterologous immunity observed.  
A direct relationship between the cross-reactive NP205-specific CD8 T cells and 
heterologous immunity between LCMV and PV still remained to be established.  
Studies have suggested that bystander T cell activation plays very little role, if 
any, in an LCMV infection (Masopust et al., 2007; Zarozinski and Welsh, 1997).  
However, the possibility that memory T cells can be activated via the induction of 

cytokines in a MHC-independent manner still remains a possible mechanism for 
heterologous immunity (Tough et al., 1996; Tsunoda et al., 2007) For example, 
one group showed that ovalbumin-specific memory CD8 T cells could confer 
protection via IFN-γ production in response to IL-12 and IL-18 following Listeria 
monocytogenes infection (Berg et al., 2003). 
Previous experimental data have suggested a role of cross-reactive 
NP205-specific CD8 T cells in mediating heterologous immunity in this system.  
First of all, memory T cells are required for heterologous immunity between 
LCMV and PV, as adoptive transfer of LCMV-specific memory donor splenocytes 
depleted of either CD4 or CD8 populations failed to show heterologous protection
(Selin et al., 1998).  Thus far, no CD4 cross-reactive epitopes have been 
identified between LCMV and PV.  Therefore, the exact role of CD4 T cells in 
heterologous immunity between LCMV and PV remains to be determined.  
Traditionally, CD4 T cells are regarded as “helper” T cells that are important to 
maintain a functional memory CD8 T cell response (Sun and Bevan, 2003; Sun 
et al., 2004).  Therefore, one possibility is that CD4 depletion of the LCMV-
immune mice could render the cross-reactive CD8 T cells functionally 

compromised.  On the other hand, CD4 T cells have been shown to possess 
cytotoxic effector functions, and they could play an important role in other 
heterologous immunity models (Jellison et al., 2005; Mathurin et al., 2009). 
Second of all, the LCMV NP205 and PV NP205 epitopes share a high aa 
sequence similarity.  In addition, previous studies from our lab have shown that 
these cross-reactive NP205-specific CD8 T cells exhibited a broad functional 
cross-reactivity and proliferated upon heterologous challenge and resulted in 
alterations of the immunodominance hierarchy (Brehm et al., 2002; Cornberg et 
al., 2006).  Finally, a significant correlation between the level of cross-reactive 
NP205-specific CD8 T cell responses and heterologous immunity can be seen in 
the homeostatic proliferation model using LCMV and PV Specifically, naïve T 
cells that had undergone homeostatic proliferation in a lymphopenic environment 
generated different magnitudes of the cross-reactive NP205-specific CD8 T cell 
responses following LCMV infection.  Therefore, we asked if there is a correlation 
between the level of cross-reactive NP205-specific CD8 T cell responses 
generated in these mice and degree of heterologous immunity following PV 
challenge.  I found a positive correlation between the magnitude of cross-reactive 

NP205-specific CD8 T cell response in each individual mouse and the level of 
heterologous immunity to PV challenge (Lin et al., 2008). 
However, the establishment of a direct link between cross-reactive 
memory T cell populations and heterologous immunity requires a direct knockout 
of the cross-reactive NP205-specific CD8 T cell responses.  This could be 
accomplished by either 1) isolation or generation of a LCMV variant that contains 
an altered version of cross-reactive NP205 CD8 epitope or 2) in vivo depletion or 
anergy induction of the putative cross-reactive CD8 T cell populations. 
Here, we hypothesized that the cross-reactive NP205-specific CD8 T cells 
are mediators of heterologous immunity between LCMV and PV.  We reasoned 
that if the cross-reactive NP205-specific CD8 T cells were directly responsible for 
heterologous immunity, a significant loss of heterologous immunity would be 
observed in LCMV NP-V207A variant-immune mice following PV challenge.  If 
our hypothesis is correct, this could be the first evidence that highlights the 
importance of cross-reactive memory T cells in mediating heterologous immunity 
in a well-characterized and controlled experimental model system. 

 
A. Limited evidence on the development of additional cross-reactive CD8 
responses in LCMV NP-V207A-immune mice challenged with PV 
Before the question of whether the cross-reactive NP205-specific CD8 T 
cells were responsible for mediating heterologous protective immunity between 
LCMV and PV could be addressed, I wanted to know if any additional cross-
reactive epitopes were present when we challenged LCMV NP-V207A-immune 
animals with PV.  Therefore, splenocytes from either LCMV WT-immune or 
LCMV NP-V207A-immune mice were CFSE-labeled and adoptively transferred 
into a group of congenic mice (Ly5.1).  Upon challenge with the heterologous 
virus (PV), cross-reactive memory T cells that express a different congenic 
marker (Ly5.2) can be monitored based on their proliferation (CFSE dilution) and 
antigen-specific cytokine responses. 
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I found an extensive proliferation (CFSE dilution) of the cross-reactive NP205-
specific CD8 T cells in congenic hosts that received wild type LCMV-immune 
splenocytes eight days after PV challenge (Figure 4.1).  However, very little 
proliferation of the cross-reactive NP205-specific CD8 T cells could be detected 
in the congenic hosts that received LCMV NP-V207A-immune splenocytes 
(Figure 4.1).  This experiment supports the conclusion drawn from previous 
chapter that cross-reactive NP205-specific CD8 T cell responses generated by 
the LCMV NP-V207A variant virus are minimal. In addition, there was no 
evidence of proliferation from other major LCMV immunodominant and 
subdominant epitope responses (GP33, NP396, GP276, GP118, and GP92) in 
congenic hosts that received splenocytes from LCMV NP-V207A-immune 
animals following PV challenge (Table 4.1).   
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However, the LCMV NP-V207A-immune splenocytes did show an extensive 
proliferation (CFSE low) and polyclonal activation via CD3 stimulation (Figure 
4.1). This could be attributed to either a small number of transferred splenocytes 
(2x107 cells per recipient) or the response to newly characterized L epitopes from 
LCMV (Kotturi et al., 2007).  Therefore, a series of experiments were conducted 
to screen for potential cross-reactive epitopes derived from the LCMV L protein.  
The preliminary experiments yielded a potential cross-reactive epitope LCMV 
L1878-1885-specific CD8 response, which displayed a similar frequency as the 
cross-reactive NP205-specific CD8 T cell response upon heterologous challenge 
(LCMV WT+PV) (Table 4.2).  However, the fact that the response to LCMV 
L1878-1885 also coincided with the diminished cross-reactive NP205-specific 
CD8 T cell response in the LCMV NP-V207A-Immune mice challenged with PV 
led me to suspect possible peptide contamination (Table 4.2). 
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  It became apparent that the initial observation was an artifact, as newly 
synthesized L1878-1885 peptide from a different source induced only a minimal 
response (Figure 4.2).  However, it was interesting to note that the overall LCMV-
specific CD8 responses was significantly higher in the peritoneal exudate cells 
(PECs) of the PV-immune mice challenged with LCMV NP-V207A as compared 
to PV-immune mice challenged with LCMV WT.  This demonstrates that the 
significant reduction in the cross-reactive NP205-specific CD8 T cell response 
could lead to the restoration of the original LCMV immunodominance hierarchy 
upon heterologous challenge of PV-immune mice (Table 4.2).  Putting these all 
together, there do not seem to be any indication of additional cross-reactive 
responses in LCMV NP-V207A variant viruses following heterologous challenge 
of PV. 
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B. The LCMV NP-V207A variant-immune mice are associated with 
significant loss of heterologous immunity to PV challenge  
To test our hypothesis that cross-reactive NP205-specific CD8 T cells 
mediate heterologous immunity between LCMV and PV, mice immunized with 
either LCMV WT or LCMV NP-V207A variant were challenged with 2x107 pfu of 
PV.  Experiments also included naïve and PV-immune control groups to compare 
the viral clearance kinetics between homologous and heterologous challenge.  
The level of heterologous protective immunity was assessed four days after PV 
challenge by monitoring the antigen-specific responses and the PV titer in 
different organs.  This early time point highlights one of the important properties 
of memory T cells, in which they are able to respond to their cognate peptides in 
a swift manner without further co-stimulation (Veiga-Fernandes et al., 2000). 
 When we compared the PV titer between the naïve and heterologous 
challenge control (LCMV WT) four days following a PV challenge, we found a 
significantly lower PV titer in the heterologous challenge control than the naïve 
control in both the spleen and the abdominal fat pads (Fig 4.3 & 4.4).  For 
example, the PV titer was about 40 times less in the spleens of the LCMV WT-
immune group as compared to the naïve control in this particular experiment 

(p<0.05) (Figure 4.3).  Similarly, the PV titer was 30 times less in the abdominal 
fat pads of the LCMV WT-immune group as compared to the naïve control 
(p<0.0001) (Figure 4.4).  Although the level of heterologous immunity in different 
organs can vary in different experiments, the LCMV WT-immune groups 
consistently displayed a significant reduction in PV titer as compared to naïve 
controls (Table 4.3).  These data recapitulate our original observation showing 
heterologous immunity between LCMV and PV (Selin et al., 1998).  On average, 
the LCMV WT-immune animal contains about 3 to 40 fold lower PV titer in either 
the spleen or the abdominal fat pad compared to the naïve control group four 
days following PV challenge (Table 4.3). 
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On the other hand, we observed a significantly higher level of PV titer in either 
the spleen or the abdominal fat pad of the LCMV NP-V207A-immune group as 
compared to the LCMV WT-immune group (Figure 4.3 & 4.4).  These data 
indicate that there is a significant loss of heterologous immunity in the LCMV NP-
V207A-immune group following a PV challenge.  Specifically, the PV titer in the 
spleens of the LCMV NP-V207A-immune group is about 13 times higher than 
that of the LCMV WT-immune group (p<0.05) (Figure 4.3).  Similarly, the PV titer 
in the abdominal fat pad of the LCMV NP-V207A-immune group is 20 times 
higher than that of the LCMV WT-immune group (p<0.0001) (Figure 4.4).  In 
addition, the PV titer in the LCMV NP-V207A-immune group often reached the 
same level as the naïve control group in both spleens and the abdominal fat pads 
(Table 4.3).  These data show that the LCMV NP-V207A-immune groups are 
associated with significant losses of heterologous immunity upon PV challenge.  
In addition, these data also suggest that the cross-reactive NP205-specific CD8 
T cells could be responsible for the most of the heterologous immunity between 
LCMV and PV.  Finally, when we compared the kinetics of PV clearance between 
the homologous challenged group (PV+PV) and the heterologous challenge 

group (LCMV+PV), these data suggest that PV clearance kinetics are 
significantly delayed in cross-reactive NP205-specific CD8 T cell-mediated 
heterologous immunity as compared to the homologous challenge group.  This 
might imply that the dominant PV NP38-specific CD8 T cells in the PV immune 
animals play a more important role in protection (Table 4.3, experiment 5 & 6). 
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On average, the frequency of the cross-reactive NP205-specific CD8 T cells in 
the LCMV WT-immune mice prior to heterologous infection accounted for 0.4% 
to 1% of the total CD8 responses by intracellular cytokine staining (ICS) (Figure 
4.5, n=5).  On the other hand, the frequency of the cross-reactive NP205-specific 
CD8 T cells in the LCMV NP-V207A-immune mice remains undetectable (Figure 
4.5).  This supports our original hypothesis that the cross-reactive NP205-specific 
CD8 T cells could be mediating heterologous immunity between LCMV and PV 
(Table 4.4).  In some experiments, a significant difference in the GP33 and 
NP396-specific CD8 T cell frequencies can be found between the LCMV WT and 
the LCMV NP-V207A groups.  However, these antigen-specific CD8 T cells have 
not been shown to be cross-reactive with PV (Table 4.4).  On the same note, the 
PV NP38-specific CD8 T cell response remained undetectable at day four in all 
three groups (naïve, LCMV WT and LCMV NP-V207A) (Table 4.4).  Finally, both 
the protection data and the antigen specific CD8 T cell frequency data support 
our hypothesis that the cross-reactive NP205-specific CD8 T cells mediate 
heterologous immunity between LCMV and PV. 
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Part II 
In part one of this chapter, I showed that LCMV NP-V207A variant-
infected mice are associated with a significant loss of heterologous immunity to 
PV challenge.  This suggests that the cross-reactive NP205-specific CD8 T cells 
are mediators of heterologous immunity between LCMV and PV.  However, we 
wanted to examine this issue more closely.  First, it is possible that the LCMV 
NP-V207A variant virus contains additional mutations other than the mutation in 
the NP205 epitope as compared to the LCMV WT virus.  Second, the original 
heterologous protection experiments were performed in the LCMV Armstrong 
background (Selin et al., 1998), whereas the mutant virus was derived from the 
LCMV clone 13 background.  Therefore, we also wanted to make sure that the 
loss of heterologous immunity observed with the LCMV NP-V207A variant is not 
a result of the virus strain tested.  In order to address these questions, 
collaboration was initiated with Dr. Juan Carlos de la Torre at the Scripps 
Research Institute.  The in vitro arenavirus rescue system that he developed 
provides a quick way to manipulate the LCMV genome through reverse genetic 

techniques (Sanchez and de la Torre, 2006) (Figure 4.6).  Using this system, we 
asked if the point mutation found within the LCMV NP-V207A could account for 
the same phenotype in the LCMV Armstrong background.  In addition, a proper 
wild type control in LCMV Armstrong (r/WT) background is also generated in 
vitro. 
 
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C.  A single point mutation in the r/V207A variant results in a greatly 
diminished cross-reactive NP205-specific CD8 T cell response in B6 mice 
 Following the successful in vitro generation and sequence verification of 
the rescue variant that contains the original (V-A) mutation (r/V207A variant 
virus), the r/V207A variant virus was tested for in vivo response in B6 mice.  I 
found that infection of B6 mice with the r/V207A variant virus resulted in greatly 
diminished cross-reactive NP205-specific CD8 T cell responses (LCMV NP205, 
PV NP205, and LCMV NP205 V-A) as compared to the r/WT control (p=0.0002) 
(Figure 4.7 & 4.8).  The LCMV NP205-specific CD8 T cell response induced by 
r/WT virus accounted for 1.7% of the CD8 T cell response as detected by IFNγ 
ICS at day eight post-infection (Figure 4.7).  On the other hand, the LCMV 
NP205-specific CD8 T cell response induced by the r/V207A variant accounted 
for only 0.4% of the CD8 T cell response by IFNγ ICS (Figure 4.7).  The 
responses from two of the major LCMV CD8 epitopes (GP33 & NP396) were 
similar between r/WT and r/V207A-immunized group (Figure 4.7 & 4.8). 
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Furthermore, PV infection of the r/V207A-immune mice did not result in any 
sizeable expansion of the cross-reactive NP205-specific CD8 T cell responses 
(Figure 4.9).  This small antigen-specific CD8 T cell response to its natural LCMV 
NP205 (V-A) ligand in the r/V207A variant infected mice could either be due to a 
loss in immunogenicity or an altered response that was not picked up by the IFNγ 
ICS assay.  To address this concern, MHC-Ig dimer studies using either LCMV 
NP205 or LCMV NP205 (V-A) peptides were done to correlate with the ICS data.  
In the mice infected with the r/WT virus, similar frequencies of antigen-specific 
CD8 T cells were detected using either LCMV NP205 MHC-Ig dimer or LCMV 
NP205 (V-A) MHC-Ig dimer at the peak of the LCMV-specific response (2.0±0.1 
vs. 1.8±0.25 respectively)  (Figure 4.10 & 4.11).   

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This is reminiscent of the peptide titration experiment comparing the efficiency 
between the LCMV NP205 and the LCMV NP205 (V-A) peptides in chapter one 
(Figure 3.6), where we initially observed a similar level of IFN-γ response using 
either peptides at an optimal (saturating) concentration range (5μM).  On the 
other hand, both types of MHC-Ig dimers were able to detect only a very small 
frequency of the antigen specific CD8 T cells in mice infected with the r/V207A 
variant virus (0.2±0 vs. 0.2±0 respectively) (Figure 4.10 & 4.11).  Therefore, a 
significantly diminished cross-reactive NP205-specific CD8 T cell response was 
not the result of a previously unidentifiable immune response, but a direct 
consequence of the loss in immunogenicity.  
  
D.  The r/WT and r/V207A variant viruses display similar activation and 
replication kinetics in B6 mice 
 To find out whether the r/WT and r/V207A viruses behave phenotypically 
in a similar fashion, time course experiments were conducted.  No significant 
difference in virus titer could be detected between the r/WT and r/V207A infected 
groups three days post-infection (Figure 4.13).  In addition, both groups cleared 
the virus by day eight post-infection, and no signs of viral persistence could be 

found in the spleens and abdominal fat pads by plaque assay (Figure 4.13).  
Again, the magnitude of the antigen-specific CD8 T cell response from both 
groups of mice peaked at around day eight post-infection and decreased 
substantially in the memory phase (Figure 4.12).  Therefore, the point mutation in 
the r/V207A virus does not seem to affect the general replication characteristics 
of the LCMV Armstrong strain virus. 

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E. Limited evidence on the development of additional cross-reactive CD8 
responses in r/V207A-immune mice challenged with PV 
Since the new system was generated in the LCMV Armstrong 
background, I wanted to know if there were any additional CD8 cross-reactive 
responses present in the r/V207A-Immune mice challenged with PV.  When I 
compared the day eight antigen-specific CD8 responses from the acutely 
challenged groups (either r/WT or r/V207A) and the heterologous challenge 
groups (r/WT+PV and r/V207A+PV), there was very little indication of additional 
cross-reactive CD8 epitopes.  As shown in figure 4.14 and 4.15, the peptide 
screening experiment using the majority of the known LCMV-specific CD8 
epitopes plus the newly identified CD8 epitopes from the LCMV L protein suggest 
that the cross-reactive NP205-specific CD8 T cell response probably accounts for 
the majority of the cross-reactive response between LCMV and PV. 
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F.  A significant loss of heterologous immunity in the r/V207A variant-
immune mice upon PV challenge 
 The rescue LCMV Armstrong variant was generated to provide further 
evidence that a greatly diminished cross-reactive NP205-specific CD8 T cell 
response results in a significant loss of heterologous immunity to PV challenge in 
the LCMV NP-V207A-immune mice.  I anticipated that a significant loss of 
heterologous immunity to PV would be observed in the r/V207A-immune mice 
challenged with PV.  If this hypothesis is true, these data would indicate that the 
cross-reactive NP205-specific CD8 T cells are mediators of heterologous 
immunity between LCMV and PV.  Therefore, I set up an identical heterologous 
challenge experiment using this rescued LCMV system.  PV challenge of the 
r/V207A-immune mice resulted in significant loss of heterologous immunity in 
both spleens and fat pads (Figure 4.16).  No statistically significant difference in 
PV titer was observed in the spleens and fat pads of the naïve control and the 
r/V207A-immune group (Figure 4.16).  On the other hand, PV challenge of the 
r/WT immune mice resulted in approximately a 6.3 and 3.2 fold reduction in PV 
virus titer in the spleens and fat pads, respectively (Figure 4.16).  Thus, these 

data support the conclusion that cross-reactive NP205-specific CD8 T cell 
populations mediate a majority of the heterologous immunity between LCMV and 
PV. 

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 Chapter Summary 
 
 One of the important questions regarding T cell cross-reactivity and 
heterologous protective immunity is whether these memory T cell populations are 
directly involved in heterologous immunity.  Here, I used the LCMV NP-V207A 
CTL escape variant that exhibited a greatly diminished cross-reactive NP205-
specific CD8 T cell response to address this particular question.  I found LCMV 
NP-V207A-immune mice are associated with a significant loss of heterologous 
immunity to PV (Figures 4.3 & 4.4).  In addition, the overall magnitude (naïve vs. 
LCMV NP-V207A) of the loss of heterologous immunity in the LCMV NP-V207A-
immune mice also suggested that the cross-reactive NP205-specific CD8 T cells 
account for the majority of the heterologous immunity.  This observation is in 
agreement with our previous adoptive transfer experiments showing that there 
were limited indications of additional cross-reactive epitopes present even in the 
absence of greatly diminished cross-reactive NP205-specific CD8 T cell 
responses (Table 4.1).  The fact that there is an extensive proliferation (CFSE 
low) of adoptively transferred splenocyte populations from LCMV NP-V207A 

donors following PV challenge suggestes that there is a possibility of additional 
cross-reactive CD8 epitopes (Fig 4.1).  However, one could argue that there are 
some technical issues involving the readout.  First of all, a small population of 
cross-reactive T cells that undergoes few rounds of division could appear to be 
the major CFSE low population due to the small number of donor splenocytes 
transferred.  Therefore, CFSE readout might lead to an over-estimation of the 
magnitude of the overall proliferative response.  Second of all, the use of CD8a 
and Ly5.2 congenic marker for tracking of the donor population represents an 
over-estimation of the antigen-specific T cells since CD45.2 (Ly5.2) markers are 
expressed on virtually all leukocytes.  For example, CD45 can be found on the 
surface of hematopoietic stems cells, NK cells, B cells and T cells (Cook et al., 
1987; Ledbetter et al., 1985).  In addition, CD8a can be found on the surface of 
dendritic cells and T cells (Tailor et al., 2006).  Therefore, our data suggest that 
the cross-reactive NP205-specific CD8 T cells are responsible for the majority of 
heterologous immunity between LCMV and PV. 
Although we feel confident that a greatly diminished cross-reactive 
NP205-specific CD8 T cell response with the LCMV NP-V207A variant is the 

direct consequence of the point mutation within the LCMV NP205 epitope, it was 
difficult to prove that additional mutations didn’t exist in the LCMV NP-V207A 
variant.  In addition, we also wanted to find out if the loss of heterologous 
immunity in the LCMV NP-V207A-immune mice could also be seen in a different 
LCMV background.  Therefore, collaboration was initiated with Dr. Juan Carlos 
de la Torre at Scripps Research Institute, who specializes in rescuing LCMV 
entirely from plasmids in vitro using reverse genetics.  The r/V207A variant virus 
that contains the original mutation exhibited the phenotype that we anticipated, 
as infection of B6 mice also results in a greatly diminished cross-reactive NP205-
specific CD8 T cell response (Figures 4.7 & 4.8).  In addition, the MHC-Ig dimer 
studies also support our overall conclusion that the mutated LCMV NP205 (V-A) 
is significantly less immunogenic (Figures 4.10 & 4.11).  Finally, the heterologous 
challenge experiment using the rescued virus system displayed essentially the 
same result as the LCMV clone 13 system (Figure 4.16).  Therefore, the loss of 
heterologous immunity to PV in the r/V207A-immune mice indicates that the 
cross-reactive NP205-specific CD8 T cells account for the majority of 
heterologous immunity between LCMV and PV.  In addition, bystander T cell 
	
activation does not seem to play a role in the heterologous immunity between 
LCMV and PV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Chapter V 
Contribution of the Cross-Reactive NP205-Specific CD8 T Cells 
To Immune Pathogenesis Following Sequential Heterologous 
Infections 
Our data from chapter four showed that the cross-reactive NP205-specific 
CD8 T cells could mediate the majority of heterologous immunity between LCMV 
and PV.  In addition, I also found that PV clearance kinetics mediated by these 
cross-reactive NP205-specific CD8 T cells is significantly delayed in comparison 
to a homologous challenge (PV+PV) (Figure 5.1).  These data suggest that the 
cross-reactive NP205-specific CD8 T cells might not be the default antigen-
specific CD8 T cell populations for clearance of PV.  Heterologous immunity is 
often associated with a partial reduction in viral replication and alteration in 
immune pathology.  In both the systemic and respiratory models that involve 
LCMV and VV, cross-reactive memory CD8 T cells have been implicated in 
altered immune pathology at the site of infection (Chen et al., 2001a; Selin et al., 
1998).  Furthermore, IAV-immune animals challenged with either LCMV or 
murine cytomegalovirus virus (MCMV) had elevated viral titer and more severe 
clinical pathology (Chen et al., 2003).  Similarly, cross-reactive T cells have been 
implicated in some of the clinical manifestations of infection in humans.  For 

example, it has been proposed that part of the clinical manifestations of dengue 
hemorrhagic fever or dengue shock syndrome might be due to memory cross-
reactive CD8 T cells from one serotype that are able to recognize a slight variant 
form of the epitope (Imrie et al., 2007).  In addition, T cell cross-reactivity 
between IAV and HCV has been hypothesized to be a mediator of severe liver 
pathology in some individuals acutely infected with HCV (Urbani et al., 2005).  
Finally, our group has also identified CD8 cross-reactive epitopes between IAV 
and EBV, and this T cell cross-reactivity has been suggested to contribute to 
lympho-proliferative disease following EBV infection (Clute et al., 2005). 
Our data showed that in mice that are sequentially immunized with PV and 
then LCMV (double immune), they developed a high incidence and severity of 
AFN following a final PV challenge.  In addition, in some cases a loss of 
protective immunity in these double immune mice was observed upon PV re-
challenge.  Since the T cell memory compartment in these double immune mice 
are dominated by cross-reactive NP205-specific CD8 T cells, they could 
constitute sub-optimal protection.  Therefore, we hypothesized that a significant 
number of the sub-optimal cross-reactive NP205-specific CD8 T cells from the 

double immune mice (PV+LCMV WT) could contribute to immune-pathology 
upon PV challenge. 
 

A 
B
 
F
ig
u
re
 5
.1
  
C
ro
s
s
-r
e
a
c
ti
v
e
 N
P
2
0
5
-s
p
e
c
if
ic
 C
D
8
 T
 c
e
ll-
m
e
d
ia
te
d
 h
e
te
ro
lo
g
o
u
s
 i
m
m
u
n
it
y
 d
is
p
la
y
s
 s
ig
n
if
ic
a
n
tl
y
 
d
e
la
y
e
d
 P
V
 c
le
a
ra
n
c
e
 k
in
e
ti
c
s
 c
o
m
p
a
re
d
 t
o
 h
o
m
o
lo
g
o
u
s
 c
h
a
lle
n
g
e
. 
 N
a
ïv
e
, 
P
V
-i
m
m
u
n
e
, 
L
C
M
V
 W
T
-I
m
m
u
n
e
, 
a
n
d
 L
C
M
V
 N
P
-V
2
0
7
A
-I
m
m
u
n
e
 a
n
im
a
ls
 w
e
re
 c
h
a
lle
n
g
e
d
 i
.p
. 
w
it
h
 2
x
1
0
7
 p
fu
 o
f 
P
V
. 
(A
) 
s
p
le
e
n
s
 a
n
d
 (
B
) 
fa
t 
p
a
d
 
fr
o
m
 
e
a
c
h
 
g
ro
u
p
 
w
e
re
 
h
a
rv
e
s
te
d
 
4
 
d
a
y
s
 
la
te
r 
a
n
d
 
ti
tr
a
te
d
 
b
y
 
s
ta
n
d
a
rd
 
p
la
q
u
e
 
a
s
s
a
y.
 
 
T
h
e
 
v
a
lu
e
s
 
a
re
 
e
x
p
re
s
s
e
d
 
a
s
 
L
o
g
1
0
 
(p
fu
/m
l)
 
±
 
S
D
. 
 T
h
e
 
a
s
te
ri
s
k
 
re
p
re
s
e
n
ts
 
a
 
s
ta
ti
s
ti
c
a
lly
 
s
ig
n
if
ic
a
n
t 
d
iff
e
re
n
c
e
 
(p
<
0
.0
5
) 
b
e
tw
e
e
n
 t
h
e
 i
n
d
ic
a
te
d
 g
ro
u
p
s
 b
y
 o
n
e
 w
a
y
 A
n
o
v
a
 a
n
a
ly
s
is
. 
 T
h
e
s
e
 d
a
ta
 a
re
 f
ro
m
 5
 m
ic
e
 p
e
r 
g
ro
u
p
. 
Log
10
 (pfu/ml) 
* 
* 
* 
* 
* 
* 
* 
* 
* 
S
P
L
E
E
N
 
F
A
T
 P
A
D
 

The question of whether the subdominant NP205-specific CD8 T cell response 
can mediate protection as efficiently as other dominant epitopes was addressed 
by using both the minigene expression and the recombinant vaccinia systems 
(van der Most et al., 1998).  Their results suggested that immunization with the 
subdominant LCMV NP205 epitope using either a peptide-conjugate or a 
recombinant vaccinia virus system can confer protection to a high dose LCMV 
clone 13 challenge, but the viral clearance rate is much slower than immunization 
with dominant LCMV epitopes (van der Most et al., 1998).  Therefore, this 
suggests that even in a homologous challenge (LCMV + Clone 13), LCMV 
NP205-mediated viral clearance might be sub-optimal.  However, this might not 
necessarily suggest that the NP205-specific CD8 T cells are inherently less 
efficient at killing a target cell, as low expression of its cognate peptide on the 
target cell could reduce their ability to kill it. 
If our hypothesis is correct, a PV challenge of the (PV+LCMV-V207A) 
double immune mice, which contain a significantly smaller number of cross-
reactive NP205-specific CD8 T cells, should have a significantly lower incidence 
and severity of AFN.  This heterologous challenge system using LCMV and PV is 

well suited for studying CTL-mediated immune pathology for the following 
reasons.  First of all, most of the tissue pathologies in arenavirus infections are T 
cell-mediated.  Second, a well-defined cross-reactive CD8 epitope and an LCMV-
V207A variant that mimics the knockout serve as important tools in this system.  
Finally, no neutralizing antibodies have been found in PV-infected animals 
(Chanas et al., 1980; Trapido and Sanmartín, 1971). Therefore, neutralizing 
antibodies will not play a role in protection in this system. 
 
A.  Domination of the cross-reactive NP205-specific CD8 T cells in the 
(PV+LCMV WT) double immune mice 
 First we wanted to monitor the frequency of antigen specific CD8 T cells in 
the blood of the (PV+LCMV WT) and (PV+LCMV V207A) double immune mice 
before a final PV challenge.  The two antigen-specific CD8 T cell responses that I 
was interested in were the cross-reactive NP205-specific CD8 T cell response 
and the immunodominant PV NP38-specific CD8 T cell response.  The PV NP38-
specific CD8 T cell response represents the dominant CD8 T cell response in B6 
mice infected with PV.  However, following a heterologous challenge with LCMV, 
a process known as memory cell attrition takes place via type I interferon 

induction by the viral infection (Bahl et al., 2006; Selin et al., 1999).  Thus, many 
of the non cross-reactive memory lymphocytes undergo attrition while the cross-
reactive memory lymphocytes that survive attrition actively proliferate.  This 
results in a highly disproportionate ratio between the cross-reactive NP205-
specific CD8 T cells and PV NP38-specific CD8 T cells in the (PV+LCMV WT) 
double immune mice.  As expected, the cross-reactive NP205-specific CD8 T cell 
response was significantly higher in the (PV+LCMV WT) double immune mice as 
compared to the (PV+LCMV-V207A) double immune mice (p<0.0001) (Figure 
5.2).   

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The average frequency of the cross-reactive NP205-specific CD8 T cell 
responses in the (PV+LCMV WT) double immune mice by ICS was 
approximately 9.5%±6.0 (n=18) (Figure 5.2).  This variation in cross-reactive 
NP205-specific CD8 T cell response reflects the private specificity of each 
individual mouse (Cornberg et al., 2006).  Typically, PV NP205-specific CD8 T 
cells display a co-dominant Vβ usage of Vβ 5.1/5.2 and Vβ 16 in PV-immune 
mice.  However, different variations of Vβ usage of the cross-reactive NP205-
specific CD8 T cells can be found in each individual PV-immune mouse following 
a heterologous challenge with LCMV.  Adoptive transfer experiments showed 
that recipients who received the same LCMV-specific memory donor splenocytes 
developed similar magnitude of cross-reactive NP205-specific CD8 T cell 
response following PV challenge, demonstrating that the private TCR repertoire 
can influence T cell clonal dominance and heterologous immunity.  On the other 
hand, the frequency of the cross-reactive NP205-specific CD8 T cells in the 
(PV+LCMV-V207A) double immune mice was about 1.1%±0.8 (n=20) (Figure 
5.2).  We did not detect a significant difference in the frequency of the PV NP38-
specific CD8 T cell response in both groups of mice in the majority of the 
	
experiments (Table 5.1).  Therefore, this non cross-reactive memory population 
in both groups of mice underwent attrition following heterologous immunization 
(Table 5.1).  In addition, the frequencies of other dominant LCMV CD8 epitopes 
were very similar in both groups of mice (Table 5.1). 
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B.  The (PV+WT) double immune mice have a significantly higher 
occurrence of AFN as compared to the (PV+LCMV-V207A) double immune 
mice following PV challenge  
 When I compared the incidence of AFN between (PV+LCMV WT) and 
(PV+LCMV-V207A) double immune mice following a PV challenge, I found a 
significantly higher frequency of AFN in the (PV+LCMV WT) double immune mice 
(p=0.0056, Mann-Whitney U test) (Figure 5.3).  The majority (74%) of the 
(PV+LCMV WT) double immune (n=23) mice displayed various clinical grades of 
AFN as compared to 38% in the (PV+LCMV-V207A) double immune mice (n=25) 
(Figure 5.3).  In addition, the overall severity of AFN appeared to be higher in the 
(PV+LCMV WT) double immune mice challenged with PV (Figure 5.3).   
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Although the PV titer in the naïve group usually reached the level of 103 or 104 
pfu/ml in both the spleens and the abdominal fat pads (Table 4.3), no AFN was 
detected four days post-infection (n=20).  This illustrates that in a viral system 
where the virus itself is non-cytolytic, the immune system of the host plays an 
important role in pathology {Oldstone, 1970, p21619}.  It was interesting to note 
that no PV could be detected in either the spleens or the abdominal fat pads of 
the (PV+LCMV WT) and (PV+LCMV-V207A) double immune mice in all the 
experiments four days following the PV challenge (n=23 and 24 respectively).  It 
is possible that the presence of both cross-reactive NP205 and non-cross-
reactive PV NP38-specific CD8 T cells could change the PV clearance kinetics in 
both groups of double immune animals.  Therefore, an earlier time point harvest 
might be required to detect PV titer in these two groups of animals.  Overall, 
these data re-affirm our initial observation that there is a high incidence of AFN in 
the (PV+LCMV WT) double immune mice following a PV challenge.  Most 
importantly, a significant difference in the frequency of AFN between (PV+LCMV 
WT) and (PV+LCMV-V207A) double immune mice suggests that these cross-
reactive NP205-specific CD8 T cells are important contributors to immune 

pathology upon PV challenge (Figure 5.3).  Since a small cross-reactive NP205-
specific CD8 T cell response could still be detected in the (PV+LCMV NP-V207A) 
double immune mice (Table 5.1), it could still be argued that an “altered” variant 
cross-reactive NP205-specific CD8 T cell response plays an un-anticipated role 
in mediating immune pathology.  Therefore, generation of in vitro rescued NP205 
epitope variants that contain alanine mutation(s) at the anchoring residue 
positions is underway to address this question.  We anticipate that alanine 
substitution at the Kb-restricted anchoring residues of the LCMV NP205 epitope 
could result in loss of MHC binding.  In vitro MHC stabilization experiments using 
different variations of LCMV NP205 peptides will be described in section F of this 
chapter.  Finally, generation of a rescued LCMV variant that results in a 
“complete NP205 knockout” phenotype would help to clarify the role of the cross-
reactive NP205-specific CD8 T cells in immune pathogenesis. 
 
 
  

C.  Domination of the cross-reactive NP205-specific CD8 T cells in the 
pathological tissues 
Except for the dramatic difference in the frequency of the cross-reactive 
NP205-specific CD8 T cell response, the overall antigen-specific CD8 T cell 
responses in either (PV+WT) and (PV+LCMV NP-V207A) double immune mice 
following PV challenge are very comparable (Table 5.2).  This suggests that the 
cross-reactive NP205-specific CD8 T cell populations still dominate the response 
in the (PV+LCMV WT) double immune mice following PV challenge. 
 In order to establish more direct evidence that the cross-reactive NP205-
specific CD8 T cells are involved in AFN, I wanted to find out if the cross-reactive 
NP205-specifc CD8 T cells are present in large percentages in the abdominal fat 
pad of the (PV+LCMV WT) double immune mice after PV challenge.  I compared 
the frequency of antigen-specific CD8 T cells at the pathological site between 
(PV+LCMV WT) and (PV+LCMV-V207A) double immune mice following a PV 
challenge.  As shown in figure 5.4, the cross-reactive NP205-specific CD8 T cell 
response was significantly higher in the (PV+WT) than the (PV+LCMV-V207A) 
double immune mice in the abdominal fat pad at day four following a PV 
challenge (22.2%±7.6 vs. 2.6%±1.4, respectively, p=0.0018, n=4).  In contrast, 

the frequency of the PV NP38-specific CD8 T cells does not seem to vary too 
greatly in the abdominal fat pads of the (PV+LCMV WT) and the (PV+LCMV-
V207A) double immune mice after a PV challenge (11.2%±4.4 vs. 16.4%±4.3, 
respectively, p=0.15, n=4).  It is interesting to note that a small percentage of 
CD8α+, CD44+ lymphocytes displayed a highly activated phenotype in the 
abdominal fat pads, as shown by a spontaneous release of IFNγ without any 
peptide stimulation (no stimulation in Figure 5.4).  Finally, the fact that only a very 
small frequency of antigen-specific CD8 T cells (LCMV NP205=4.1%±1.5 and PV 
NP38=3.4%±0.7, n=5) could be detected in the abdominal fat pads of the naïve 
control group four days after a PV challenge indicates the strong involvement of 
re-activating memory T cells in this pathology. 

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D.  Contribution of the cross-reactive NP205-specific CD8 T cells to 
immune pathogenesis 
 In comparison to the (PV+LCMV NP-V207A) double immune animals, the 
significantly higher occurrence of AFN and the dominating proportions of the 
cross-reactive NP205 CD8 T cell response in the (PV+LCMV WT) double 
immune mice following PV challenge supported our hypothesis that these cross-
reactive NP205-specific CD8 T cells could contribute to immune pathology.  To 
find further supporting evidence, a correlation study was conducted to look at the 
relationships between the magnitude of the cross-reactive NP205-specific CD8 T 
cell response and the severity of the immune pathology in the (PV+LCMV WT) 
double immune mice.  Based on our current hypothesis, we expected a positive 
correlation between the magnitude of the cross-reactive NP205-specific CD8 T 
cell response and severity of the AFN in the (PV+LCMV WT) double immune 
mice. 
 When I examined each individual mouse in the (PV+LCMV WT) double 
immune group and looked at the linear relationship between the frequency of the 
cross-reactive NP205-specific CD8 T cells before the final PV re-challenge and 


the severity of the AFN four days after the PV re-challenge, I found a weak 
positive correlation.  However, the correlation was not statistically significant 
(Figure 5.5).  The reasons could be the following.  First of all, a natural variation 
in the magnitude of the cross-reactive NP205-specific CD8 T cell response 
known as private specificity in each individual mouse could dramatically impact 
the association.  Second of all, the development of pathology could be a multi-
cellular and multi-factorial process.  Therefore, one might need to take into 
account the possibility that there are other cellular factors involved.  Finally, it 
could be a combination of both factors mentioned above. 
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 The PV NP38-specific CD8 T cell response represents a dominant CD8 
response following a PV infection, whereas the PV NP205 is subdominant.  
Following a homologous challenge (PV+PV), the frequency of the memory T cell 
populations are boosted accordingly and the hierarchy is maintained.  However, 
following a heterologous challenge (PV+LCMV WT), the cross-reactive NP205-
specific CD8 T cell population preferentially expands and dominates the 
response while the non cross-reactive PV NP38-specific CD8 T cells undergo 
attrition (Selin et al., 1999) Therefore, it is possible that a dramatic switch in the 
hierarchy (frequency) and interplay between these two CD8 T cell populations 
could ultimately decide the pathological outcome of the (PV+LCMV WT) double 
immune mice. 
Therefore, I wanted to find out if there was any correlation between the PV 
NP38-specific CD8 T cells and the severity of the AFN in the same group of 
(PV+LCMV WT) double immune mice.  Interestingly, there was a significant 
negative correlation (p=0.02, n=18) when I compared the frequency of the PV 

NP38-specific CD8 T cell response to the severity of the AFN in the (PV+LCMV 
WT) double immune mice (Figure 5.6).  In addition, if I took the ratio between the 
cross-reactive NP205-specific CD8 T cells and the PV NP38-specific CD8 T cells 
from each individual (PV+LCMV WT) double immune mouse and correlated them 
with the severity of AFN, a highly significant positive linear correlation could then 
be seen (Figure 5.7, p=0.004).  This strongly suggests that PV NP38-specific 
CD8 T cell response could play a more protective role than the cross-reactive 
NP205-specific CD8 T cell response. 
	
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As a negative control, I used one of the non cross-reactive LCMV CD8 epitopes 
that would not play a role in response to PV.  No significant correlation was found 
when I compared the frequency of the LCMV GP33-specific CD8 response in the 
(PV+LCMV WT) double immune mice to the severity of the AFN (Figure 5.8).  In 
addition, I did not find any significant linear correlation between the GP33/NP38 
ratio and the level of AFN (Figure 5.8).  This suggests that the non cross-reactive 
GP33-specific CD8 T cells do not play a role in immune pathogenesis in the 
(PV+WT) double immune mice following a PV challenge.   
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 Therefore, the induction of pathology might depend on either a direct or indirect 
interplay between these two CD8 T cell populations.  Finally, the correlation data 
support our hypothesis that the cross-reactive NP205-specific CD8 T cells are 
important contributors to immune pathology in this model. 
?
E.  Similar level of functional avidity between the cross-reactive NP205 and 
PV NP38-specific CD8 T cells in the (PV+LCMV WT) double immune mice 
The correlation data suggest that the cross-reactive NP205-specific CD8 T 
cells might interfere with PV NP38-specific CD8 T cells.  For example, I showed 
that there was a significant delay in PV clearance comparing to homologous 
challenge (Fig 5.1).  This might reflect an intrinsic property of the cross-reactive 
NP205-specific CD8 T cells or a different level of epitope expression on the APC.  
Therefore, I asked if there were any fundamental differences between these two 
CD8 T cell populations.  Functional avidity studies employing different 
concentrations of peptide for stimulation of effector cells are often used to 
estimate the affinity of the TCR:pMHC interaction.  High avidity antigen-specific T 
cell clones are usually regarded as the elite controllers of viral infections (Neveu 
et al., 2008).  On the other hand, antigen-specific T cells that have a low affinity 
		
TCR are implicated in many autoimmunity models and are associated with 
immune pathology (Harkiolaki et al., 2009; Zehn and Bevan, 2006).  Hence, I 
was interested in finding out if there were functional avidity differences between 
the cross-reactive NP205-specific CD8 T cells and the PV NP38-specific CD8 T 
cells in the (PV+WT) double immune mice.  Therefore, I isolated splenocytes 
from the (PV+WT) double immune mice and stimulated them separately with 
gradients of the LCMV NP205, PV NP205, and PV NP38 peptides.  The 
difference in functional avidity was accessed by comparing the peptide 
concentration required to elicit 50% of the maximum IFNγ response in each of 
the antigen-specific CD8 T cells.  I found that the functional avidities of the cross-
reactive NP205-specific CD8 T cells and the PV NP38-specific CD8 T cells are 
quite comparable in 3 out of 4 (PV+WT) double immune mice (Figure 5.9). 
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However, it is interesting to note that the functional avidity for PV NP205-specific 
CD8 T cells was lowest among the 3 responses.  Therefore, it is possible that the 
sequence of immunization (PV+LCMV WT) generates a cross-reactive NP205-
specific CD8 T cell population more sensitive to the LCMV NP205 epitope.  
However, a more precise analysis is needed to conclude that this finding is 
significant.  Based on this experiment, both cross-reactive NP205-specifIc CD8 T 
cells and the PV NP38-specific CD8 T cells are high avidity T cells that display 
very little difference in their respective peptide sensitivity (Figure 5.9).  
Occasionally, there could be a situation where the cross-reactive NP205-specific 
CD8 T cell populations have a significantly lower functional avidity than the PV 
NP38-specific CD8 T cell populations (Figure 5.9).  Again, this observation 
highlights the private specificity of the cross-reactive NP205-specific CD8 T cell 
population in each individual mouse.  This observation could provide one of the 
mechanistic explanations on how the cross-reactive NP205-specific CD8 T cells 
are associated with immune pathology.  However, the difference in the overall 
level of antigenic epitope expression on the cell surface could still be a major 
	
reason why there is a significant delay in cross-reactive NP205-specific CD8 T 
cell-mediated PV clearance. 
?
F.  Kb stabilization assay of LCMV NP205 peptides containing alanine 
mutated anchoring residues  
 In addition to the r/V207A variant virus that contains the original point 
mutation from the LCMV NP-V207A variant virus, I also experimented with the 
possibility of generating a NP205 epitope variant that contains mutation(s) at the 
anchoring residue positions (Figure 4.6).  Despite the possibility that the LCMV 
NP205 (V-A) peptide can still be presented in vivo (Figure 3.5), both ICS and 
MHC-Ig dimer experiments suggested that the point mutation resulted in a 
significant but not complete loss in immunogenicity (Figure 4.10 & 4.11).  The low 
incidence of AFN seen in the (PV+LCMV NP-V207A) double immune mice 
following PV challenge could still be attributed to this small but “altered” NP205 
response.  Therefore we wanted to construct a LCMV NP205 variant virus that 
lacks the ability to present the cross-reactive NP205 epitope on the cell surface.  
Different versions of the LCMV NP205 peptides containing either single alanine 
	
substitution at one of the two Kb anchoring residues (positions six and eight) or 
alanine residues at both anchoring positions were synthesized (Figure 5.10).   
 
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Subsequently, a MHC stabilization assay was performed on each peptide to 
estimate its ability to bind to Kb.  The 50% maximum binding curve indicates that 
there was a significant reduction among these alanine switched peptides in their 
ability to stabilize Kb (Figure 5.10).  The original LCMV NP205 (V-A) peptide has 
a 50% maximum binding capacity at approximately 0.05μM.  On the other hand, 
the 50% maximum binding capacity for the LCMV NP205 peptides with an 
alanine at either anchoring residue was at the 5μM range, correlating to a 
hundred-fold reduction in the ability to stabilize Kb (Figure 5.10).  As predicted, 
the LCMV NP205 peptide that contained alanine in both anchoring residues 
displayed the most dramatic reduction in Kb binding ability, as its Kb MFI was only 
slightly above the un-pulsed control (720 vs. 500) at a 100μM concentration 
(Figure 5.10).  Therefore, these data provide first hand evidence that some of the 
alanine switch mutations in the LCMV NP205 epitope could result in a LCMV 
variant with a “complete knockout” version of the NP205 epitope.  So far, I have 
been able to generate two rescued variant viral stocks that contain a single 
alanine mutation in either one of the anchoring residues of Kb (r/Y209A and 
r/L212A).  My preliminary data show that the antigen-specific CD8 response in 


mice immunized with r/L212A variant did not respond to any of the LCMV NP205 
variant peptides by standard ICS assay (LCMV NP205, PV NP205, LCMV NP-
Y209A, and LCMV NP-L212A).  The “complete knockout” of the LCMV NP205 
CD8 epitope would enable us to further clarify the nature of the diminished 
NP205 responses elicited by the LCMV NP-V207A variant. 
 
Chapter Summary 
 
Much evidence suggests that cross-reactive T cells are associated with 
immune pathology.  In many of the autoimmune models, cross-reactive memory 
T cells previously primed by pathogens expressing epitopes that closely 
resemble self-antigen are the major mediators of autoimmune tissue destruction 
(Lünemann et al., 2008).  Our data from chapter four suggest that the cross-
reactive NP205-specific CD8 T cell population mediates the majority of the 
heterologous immunity in this system without any apparent immune pathology.  
However, a significantly delayed PV clearance kinetics by the cross-reactive 


NP205-mediated heterologous immunity can be seen compared to the 
homologous challenge control (PV+PV) (Figure 5.1). 
In (PV+LCMV) double immune hosts re-challenged with PV, a high 
incidence of AFN was observed.  Therefore, I questioned whether the presence 
of a large number of subdominant cross-reactive NP205-specific CD8 T cells in 
the (PV+LCMV) double immune mouse might be responsible for development of 
AFN.  Overall, my data suggest that the cross-reactive NP205-specific CD8 T 
cells in the (LCMV+PV) double immune mice are significant contributors to 
immune pathogenesis following PV challenge.  First of all, I found that the 
incidence and magnitude of AFN is significantly higher in the (PV+LCMV) than 
the (PV+LCMV NP-V207A) double immune mice (Figure 5.3).  In addition, the 
cross-reactive NP205-specific CD8 T cells are the dominant responders in the 
primary site of infection in the (PV+LCMV) double immune mice upon a PV 
challenge (Figure 5.4).  Interestingly, my correlation studies reveal that two 
important antigen-specific CD8 T cell populations (one cross-reactive, one non 
cross-reactive) in the (PV+LCMV) double immune mice might play opposing 
roles upon PV challenge.  PV NP38-specific CD8 T cells are the 


immunodominant population in the PV-immune animals.  Upon heterologous 
challenge, the immunodominance hierarchy is reversed by 1) a comprehensive 
attrition of the memory lymphocyte populations and 2) active expansion of the 
cross-reactive NP205-specific CD8 T cell populations that survive the attrition.  
Since homologous challenge appears to clear the virus much quicker than 
heterologous challenge, this would suggest that PV NP38-specific T cells are the 
default CTL response for PV viral clearance (Figure 5.1).  On the other hand, the 
cross-reactive NP205-specific CD8 T cell populations can mediate a different 
level of protection, albeit with a much slower kinetics.  Significantly delayed PV 
clearance kinetics might play an important role in the induction of immune 
pathology.  One could imagine that prolonged activation might lead to direct 
tissue pathology and possibly secondary recruitment of non antigen-specific cells 
into the pathological sites.  The exact mechanistic explanation of how the cross-
reactive T cells might contribute to immune pathology is still under investigation.  
However, we did not find a significant difference in terms of the functional avidity 
between the cross-reactive NP205-specific CD8 T cell and the PV NP38-specific 
CD8 T cells in the (PV+LCMV) double immune animals (Figure 5.9).  Therefore, 

	
these data suggest that the difference in clearance could be due to a difference 
in antigenic epitope expression.  On the other hand, whether there is a difference 
in cytokine expression profiles between these two T cell populations remains to 
be determined.  It has been shown that activation by an APL could result in 
alteration in cytokine profile in antigen-specific T cells (Bashyam et al., 2006; 
Clute et al., 2005).  Finally, these data support our hypothesis that the cross-
reactive NP205-specific CD8 T cells play an important role in immune 
pathogenesis in the LCMV and PV heterologous challenge system. 
The exact mechanism of AFN is still unknown in this system.  However, in 
the LCMV and VV system, TNF is an important cytokine for the induction of AFN.  
Work done by Siwei Nie, a former graduate student in Dr. Liisa Selin’s lab has 
shed light into some possible mechanisms.  A potential scenario has been 
postulated in this model, in which cross-reactive CD8 T cells would first 
recognize the VV-specific antigens on an APC.  This would lead to cytokine 
production (IFNγ and TNF) and FASL expression by the cross-reactive CD8 T 
cells and further TNF production by  	 
  	  signal 
through TNFR2 on the surface of adipocytes, which would lead to an increase in 



FAS expression.  When the activated CD8 T cells engage the adipocytes through 
the FAS/FASL pathways, this would induce death of adiopcytes.  Therefore, it is 
possible that TNF could play a similar role in immune-pathogenesis of the fat 
pad.  In the LCMV system, IFNγ+/TNF+ (double) producers normally account for 
approximately 70 to 90% of the total IFNγ+ producers within a given antigen-
specific CD8 T cell population.  Although the role of IFNγ has not been 
addressed in this system, frequency of IFNγ-producing antigen-specific CD8 T 
cell might provide an accurate estimation of the frequency of antigen-specific 
CD8 T cells in this system.  However, the use of MHC tetramers or dimers would 
be more useful in this regard. 
The use of the ratio between the cross-reactive NP205 and PV NP38-
specific CD8 T cell populations suggested that the induction of immune-
pathogenesis by the cross-reactive NP205-specific CD8 T cell populations is 
highly dependent on the presence of PV NP38-specific CD8 T cell.  First of all, 
the significant difference in AFN occurrence between the (PV+ LCMV WT) and 
(PV+ LCMV NP-V207A) double immune animals does suggest role of cross-
reactive NP205-specific CD8 T cells play in immune-pathogenesis.  Second of 


all, the correlation data presented in Fig 5.6 suggest that PV NP38 is a protective 
epitope.  Therefore, even a small percentage of PV NP38 can dramatically 
increase the kinetics of PV clearance.  Therefore, the use of the ratio between 
the frequency of cross-reactive NP205 and PV NP38-specific CD8 T cells 
suggest a threshold balance in terms of pathology and protection.  The data 
suggest that as the ratio between the cross-reactive NP205 and PV NP38-
specific CD8 T cells reach a point, the cross-reactive NP205-specific CD8 T cells 
could dominate the protective PV NP38-specific CD8 T cells response through a 
mechanism that is yet unknown.
One important question about this system is the possibility of T cell clonal 
exhaustion.  As our data suggest, the LCMV NP-V207A variant is able to induce 
T cell clonal exhaustion in a similar manner as LCMV clone 13 (Fig 3.11).  We 
chose the high challenge dose in order to drive the expansion of cross-reactive 
NP205-specific CD8 T cell response.  Although original reports showed the 
induction of T cell clonal exhaustion in animals that received high dose i.v. (2x106 
pfu) (Ahmed and Oldstone, 1988; Ahmed et al., 1984), the dose (1x106 pfu i.p.) 
we challenged the PV-immune mice could potentially result in partial clonal 


exhaustion. In fact, 2 animals in the PV+LCMV WT group and 1 animal in the 
PV+LCMV NP-V207A group had to be excluded from the overall data pool 
because T cell clonal exhaustion was observed in GP33 and NP396-specific 
CD8 T cell populations before PV challenge.  However, the majority of ICS data 
from both (PV+LCMV WT) and (PV+LCMV NP-V207A) double immune animals 
showed that the dose of 1x106 i.p. Induced a optimal TNF and IFNγ by the 
antigen-specific CD8 T cells (Fig 5.1 and 5.2).  However, experiments looking at 
surface expression of PD-1 on those antigen-specific CD8 T cells have not been 
performed.  Some reports have shown that IL-10 play a crucial role in controlling 
persistent virus infections, possibly through suppression of antigen-specific T cell 
responses (Brooks et al., 2008; Brooks et al., 2006).  However, there has not 
been any report on whether IL-10 might be playing a role in immune-
pathogenesis in the (PV+LCMV WT) double immune mice at the dose we 
administered i.p.  Finally, the development of AFN (pathology) in this model 
strongly argue against T cell clonal exhaustion since the pathology are usually 
dependent on T cell responses.  Most importantly, the original observation that 


cross-reactive NP205-specific CD8 T cells might contribute to immune pathology 
was conducted in the LCMV Armstrong background.   

Chapter VI 
Discussion 
 
Heterologous immunity typically displays either a delayed viral clearance 
or a change in the pattern of immune pathology due to the activation of cross-
reactive memory lymphocytes.  Although the protective side of heterologous 
immunity is often overlooked, it can be beneficial to the host.  For example, 
LCMV-immune mice can withstand a higher dose of VV challenge compared to 
naïve mice. However, these immune mice develop immune pathology in the 
abdominal fat pad known as acute fatty necrosis (Selin et al., 1998).  This 
illustrates a compromise between partial protective immunity conferred by these 
cross-reactive memory T cell populations verses the development of immune 
pathology.  In fact, some evidence from studies in humans suggested that T cell-
mediated heterologous immunity is often associated with immune pathologies 
(Clute et al., 2005; Lünemann et al., 2008; Urbani et al., 2005). 
 
One of the key features of mammalian adaptive immunity is its antigen 
specificity and quick recall response when it detects an antigen for the second 
time.  A fully differentiated memory T cell is capable of multiple effector functions 

and resembles a double-edged sword as it can either lead to clearance of the 
pathogen or immune pathology if not regulated properly.  The LCMV+PV 
heterologous immunity model represents one of the prototypical experimental 
systems to examine the nature of T cell cross-reactivity and heterologous 
immunity.  First, this system contains well-defined cross-reactive NP205 CD8 
epitopes between LCMV and PV.  The high degree in aa similarity between the 
two Kb-restricted CD8 epitopes results in a cross-reactive NP205-specific CD8 T 
cell response that is bi-directional and predictable.  Using this system, our lab 
has made fundamental observations with regard to T cell cross-reactivity and 
heterologous immunity.  First, T cell cross-reactivity between LCMV and PV 
leads to a dramatic alteration in the immunodominance hierarchy of the host 
(Brehm et al., 2002).  Second, heterologous immunity between LCMV and PV 
results in a partial protective immunity without any apparent immune pathology.  
Third, the overall cross-reactive NP205-specific CD8 TCR repertoire becomes 
extremely narrowed following a heterologous infection.  The overall aims of my 
thesis were 1) to establish a direct link between the cross-reactive NP205-
specific CD8 T cells and heterologous immunity between LCMV and PV, and 2) 

to investigate the role of cross-reactive NP205-specific CD8 T cells in immune 
pathogenesis in this heterologous immunity model.  
 
Narrowing of the TCR repertoire and generation of CTL escape variants 
Why certain antigen-specific TCR repertoires are narrower than others 
remains unclear.  As suggested by Turner et al, it is possible that inherent 
features in a given antigenic epitope can select only an antigen-specific response 
that constitutes a “narrow” TCR repertoire (Turner et al., 2005).  In addition, a 
difference in MHC polymorphism can also affect TCR repertoire selection 
(Messaoudi et al., 2002).  Messaoudi et al showed that mice expressing the Kbm8 
haplo-type are more resistant to a lethal dose of herpes simplex virus type one 
(HSV-1) challenge as compared to normal B6 mice.  This might be due to the 
fact that HSV-8p-specific CD8 T cells generated from the Kbm8 mice displayed a 
broader TCR repertoire and higher functional avidity.  On the other hand, it has 
been shown that the overall breadth of antigen-specific TCR repertoire can be 
subjected to skewing under constant activation and selection such as chronic 
viral infections or homeostatic proliferation (Lin et al., 2008). Finally, significant 
skewing of the cross-reactive NP205-specific CD8 TCR repertoires was 

observed in the LCMV+PV heterologous immunity model (Cornberg et al., 2006).  
Therefore, we predicted that under a dominant but narrowed cross-reactive 
NP205-specific CD8 T cell response, one of the immunological consequences 
would be the generation of NP205 CTL variants.   
An LCMV NP205 CTL variant (LCMV NP-V207A) was isolated in a PV-
immune mice challenged with LCMV clone 13. The mutation reflects both the 
specificity and a high degree of conservation of the NP205 epitopes between 
different arenaviruses.  The point mutation within the LCMV NP-V207A variant 
results in switching of valine to alanine at the third non-anchoring aa position of 
the NP205 epitope.  Since all the NP205 epitope aa sequences so far indicate 
that the third aa position can only be either a valine or an alanine, the mutated 
NP205 CD8 epitope now resembles the Lassa virus NP205 sequence.  Most 
importantly, immunization of B6 mice with the LCMV NP-V207A variant results in 
a greatly diminished cross-reactive NP205-specific CD8 T cell response.  This 
observation strongly suggests that this point mutation results in a dramatic loss of 
immunogenicity of the NP205 epitope. 

 To further ascertain that this mutation is responsible for the greatly 
diminished cross-reactive NP205-specific CD8 response in B6 mice, rescued 
LCMV were generated in vitro by our collaborators at the Scripps Research 
Institute using molecular biology techniques.  Again, the rescued LCMV virus 
(r/V207A) that contains the original point mutation also results in a significantly 
diminished cross-reactive NP205-specific CD8 response.  In addition, studies 
using MHC-Ig dimers loaded with either wild type LCMV NP205 or LCMV NP205 
(V-A) peptides for detection of antigen-specific CD8 T cell responses support our 
original conclusion that this mutation results in a significant reduction in LCMV 
NP205 immunogenicity. 
 Factors such as CTL strength, viral fitness, epitope structure, and the 
nature of virus all play a role in determining the emergence of a CTL escape 
variant.  Narrowing of the TCR repertoire has been associated with an increased 
frequency of viral escape variants (Charini et al., 2001; Meyer-Olson et al., 
2004).  Therefore, a dominant cross-reactive NP205-specific CD8 T cell 
response with a narrowed TCR repertoire should increase the odds of NP205 
cross-reactive CTL escape due to the reduction in the ability to recognize 
	
potential epitope variants.  Here, we demonstrated in this system that one of the 
immunological consequences of T cell mediated heterologous immunity is the 
generation of viral CTL escape variants in vivo. 
 
Cross-reactive NP205-specific CD8 T cells are mediators of heterologous 
immunity between LCMV and PV 
Previously, our lab showed that heterologous challenge between LCMV 
and PV resulted in partial protective heterologous immunity.  However, a direct 
link between the cross-reactive NP205-specific CD8 T cells and heterologous 
immunity still remained to be established.  For instance, bystander T cell 
activation has been suggested to play a role in some heterologous immunity 
models (Gilbertson et al., 2004; Polley et al., 2005).  Heterologous challenge 
experiments were carried out to test whether there was a direct link between the 
cross-reactive NP205-specific CD8 T cells and heterologous immunity in the 
LCMV+PV model.  Specifically, we reasoned that if the cross-reactive NP205-
specific CD8 T cells were directly mediating heterologous immunity between 
LCMV and PV, a significant loss in heterologous immunity should be observed in 
the LCMV NP-V207A-immune mice challenged with PV.  However, it is 


conceivable that additional cross-reactive epitopes could take a dominant role in 
the LCMV NP-V207A-immune mice challenged with PV.  Therefore, a series of 
adoptive transfer studies and peptide screening experiments were conducted to 
screen for additional cross-reactive epitopes.  Our preliminary data suggested 
that there was very little indication of additional cross-reactive CD8 epitopes in 
LCMV NP-V207A-immune mice challenged with PV.  Finally, the protection data 
derived from both systems (LCMV NP-V207A and r/V207A) suggested that the 
cross-reactive NP205-specific CD8 T cells are mediators of the majority of 
heterologous immunity between LCMV and PV.  This is the first evidence that 
cross-reactive T cells are mediators of heterologous immunity between LCMV 
and PV in vivo using a natural infection model.  In addition, it also demonstrates 
that bystander activation plays very little role, if any, in the LCMV+PV 
heterologous immunity model. 
  
Contribution of the cross-reactive NP205-specific CD8 T cells to immune 
pathogenesis  
Cross-reactive T cells are often associated with various types of tissue 
pathologies in both murine models and humans.  The central focus of my thesis 

was to address the question of how cross-reactive T cells contribute to immune 
pathogenesis.  Experiments from our lab showed that (PV+LCMV WT) double 
immune mice developed a high incidence as well as high level of AFN after a 
final challenge with PV.  These data suggest that cross-reactive NP205-specific 
CD8 T cells could play an important role in immune pathogenesis. 
The fact that we found a significantly higher incidence of AFN in the 
(PV+LCMV WT) than the (PV+LCMV NP-V207A) double immune groups support 
our hypothesis that the cross-reactive NP205-specific CD8 T cells populations 
play an important role in the development of AFN.  In addition, since a small 
percentage of (PV+LCMV NP-V207A) double immune animals still developed 
AFN following PV challenge, we question whether a small but altered cross-
reactive NP205-specific CD8 T cell response still exists within the animals.  
Therefore, generation of the rescued LCMV variants that contain the mutation(s) 
at the anchoring residues of the LCMV NP205 epitope is underway to address 
this particular question. 
 There is additional evidence to support our hypothesis.  First of all, cross-
reactive NP205-specific CD8 T cells dominate the memory pool of the 

(PV+LCMV WT) double immune mice.  In addition, these cross-reactive NP205-
specific CD8 T cells are also present at a high proportion in the pathological site 
following infection.  Normally, PV NP38 stimulates the dominant CD8 response in 
mice immunized with PV whereas PV NP205 stimulates a subdominant CD8 T 
cell response.  However, PV-immune animals challenged with LCMV resulted in 
reversal of the immunodominance hierarchy. In addition, type I IFN-induced 
attrition drives the non cross-reactive NP38-specific CD8 T cell frequency further 
down.  
Second, the correlation studies looking at linear relationships between the 
frequency of the cross-reactive NP205-specific CD8 T cells in the (PV+LCMV 
WT) double immune mice and the severity of AFN suggest that two antigen-
specific CD8 T cells might be playing opposite roles in this model.  Therefore the 
outcome of immune pathology could be decided by the interplay between these 
two CD8 T cell populations.  For example, when we looked at linear correlation 
between the PV NP38-specific CD8 T cell responses in the (PV+LCMV WT) 
double immune mice and the severity of AFN following PV challenge, we 
observed a significant negative linear correlation.  This suggests that PV NP38-

specific CD8 T cells appear to confer a protective response from immune 
pathology.  On the other hand, the linear correlation between the ratio of the 
NP205/NP38 in the (PV+LCMV WT) double immune mice and the severity of 
AFN following PV re-challenge suggests that the cross-reactive NP205-specific 
CD8 T cells play an important role in immune pathology.  
 Third, the viral protection data provide a possible mechanistic explanation 
for how the cross-reactive NP205-specific CD8 T cells might contribute to 
immune pathogenesis.  A comparison of PV clearance kinetics between 
homologous (PV+PV) and heterologous (LCMV+PV) challenge suggests that 
different antigen-specific populations might mediate different levels of protection.  
Since a homologous challenge (PV+PV) sequence clears the virus much faster 
compared to a heterologous challenge sequence (LCMV+PV), this implies that 
PV NP38-specific CD8 T cells play a more important role than the cross-reactive 
NP205-specific CD8 T cells in mediating protective immunity to PV.  Therefore, a 
significant difference in PV clearance kinetics could be the reason why it is 
possible to observe a loss in protective immunity to PV in the (PV+LCMV WT) 
double immune mice under certain conditions.   

One of the reasons why cross-reactive T cells are sometimes associated 
with immune pathology is low affinity/avidity ligand interaction.  First of all, high 
avidity TCR/pMHC interactions are more specific and are usually correlated with 
viral control (Neveu et al., 2008).  On the other hand, low affinity cross-reactive T 
cells have been implicated to play a role in dengue hemorrhagic fever, a severe 
clinical manifestation that occurs at higher frequency in individuals sequentially 
infected with two different serotypes of dengue virus (Mongkolsapaya et al., 
2003).  Studies also suggest that different autoimmune diseases are caused by 
low affinity cross-reactive T cells (Harkiolaki et al., 2009; Zehn and Bevan, 2006).  
I showed in chapter V that the overall functional avidities (cross-reactive NP205 
and PV NP38) within each (PV+LCMV WT) double immune mouse are similar 
and are considered high avidity interactions.  However, splenocytes isolated from 
one of the double immune mice displayed a very low functional avidity to PV 
NP205 peptide.  This is reminiscent of one report showing that boosting with a 
high dose of a heterologous peptide in a conventional prime-boost regimen can 
lead to CD8 T cells with low functional avidity (Narayan et al., 2007).  A low 
functional avidity to the PV NP205 peptide can also be explained by the 

sequence of immunization in these double immune mice.  Therefore, these low 
avidity cross-reactive T cells might not be able to control the virus efficiently.  
However, because the functional avidities of the cross-reactive NP205-specific 
CD8 response and the PV NP38-specific CD8 response are comparable in the 
majority of the (PV+LCMV WT) double immune mice, other factors could also 
play a role.  For example, a difference in the relative surface expression of each 
epitope represents an interesting possibility that could lead to a difference in PV 
clearance. 
 The other possible mechanism is a change in cytokine profiles following 
stimulation by a heterologous ligand. There is evidence suggesting that different 
levels of T cell activation can be modulated via APLs that display different 
characteristics.  Depending on its affinity to the TCR and overall aa sequence, an 
APL can be characterized as a full agonist, a partial agonist, and an antagonist.  
For example, different APLs of the LCMV GP33 epitope have been shown to 
elicit different levels of calcium flux in naïve GP33-specific P14 transgenic T 
cells, indicating that these naïve transgenic TCR populations could respond to 
each APL in a slightly different manner and lead to differential downstream 

effector functions (Bachmann et al., 1997).  Other reports showed that APLs 
could lead to T cell anergy through alteration of TCR signal transduction patterns 
(Sloan-Lancaster et al., 1994; Sloan-Lancaster et al., 1996).  In the LCMV 
system, there are reports showing that different variants of the GP33 epitope 
could elicit different functional responses in the antigen-specific CD8 T cells both 
in vitro and in vivo (Martin et al., 1996).  For example, different variants of the 
GP33 epitope display limited abilities to induce GP33-specific CD8 T cell killing in 
in vivo CTL assays (Bättig et al., 2005).  
APLs can play an important role in T cell mediated cross-reactivity and 
heterologous immunity.  Cross-reactive epitopes can potentially deliver partial 
TCR signals and result in alteration in T cell functions.  For example, the cross-
reactive epitope D2 variant 71-79 from type 2 dengue that acts as a partial 
agonist to DV3 immune T cells induced very little T cell proliferation and IFNγ 
production in a heterologous dengue virus infection (Zivny et al., 1999).  In 
addition, the same group also showed that there is an alteration in T cell cytokine 
profile following a heterologous peptide stimulation (Bashyam et al., 2006).  
Finally, ex vivo stimulation of auto-reactive T cells clones specific to myelin basic 

protein by an APL led to differential secretion of cytokines (Ausubel et al., 1999; 
Ausubel et al., 1997).  Similar observations were made in our lab where we found 
that a specific heterologous challenge sequence with an unrelated organism led 
a change in cytokine profile of the host (Chen et al., 2003; Clute et al., 2005). 
In conclusion, we have made the following observations in regard to the 
LCMV+PV heterologous challenge system.  First of all, the cross-reactive 
NP205-specific CD8 T cells result in the dramatic alteration in the 
immunodominance hierarchy of the second incoming virus, possibly through 
immunodomination.  Second of all, the expansion of the cross-reactive NP205-
specific CD8 T cells leads to an extremely narrowed TCR repertoire, and could 
result in generation of a viral CTL escape variant.  Third, the cross-reactive 
NP205-specific CD8 T cells are the mediators of heterologous immunity, 
associated with a significantly delayed PV clearance kinetics when compared to 
homologous challenge.  The induction of immune pathology in this system 
possibly reflects the interplay between two different antigen-specific CTL 
populations through mechanisms that are not yet described.  Finally, all the 
evidence suggests that heterologous immunity comes at a greater cost to a host 

than homologous immunity due to its association with immune pathology.  
Therefore, the caveat of heterologous immunity really falls between the extent of 
T cell-mediated immune pathology versus host survival. 
Finally, the data in this study bear important implications on the design of 
T cell vaccines in the future.  Specifically, removal of potential cross-reactive 
CD8 T cell epitopes might prove to be beneficial in certain situations.  First of all, 
T cell-mediated cross-reactive responses have the potential to bias the 
establishment of the subsequent immune response, as evidenced by the 
alteration of immunodominance hierarchy patterns (Brehm et al., 2002).  Second 
of all, a single dominant cross-reactive T cell response could lead to either viral 
escape (chapter III) or competition against a more protective response (chapter 
V).  This sub-optimal response could lead to delay in viral clearance and 
prolonged cytokine production and bystander recruitment, which together could 
contribute to induction of immune pathology (Fig 5.1). 
The difficulty in providing an accurate prediction in highly diversified 
populations such as humans lies in the fact that all the individuals have a unique 
history of vaccination and infections.  However, it might still be possible to 
	
delineate a common denominator that could provide a useful prediction in a given 
population.  For example, removal of the HCV NS3 1073-1081 cross-reactive 
epitope, which cross-reacts with IAV NA 231-239, might prove to be beneficial to 
the majority of HLA-A2-restricted individuals receiving HCV vaccine in the future 
since most of them will contain potential cross-reactive memory T cell 
populations from either IAV immunization or infections.  Furthermore, therapeutic 
interventions that aim at elimination of the cross-reactive memory T cell 
populations could also be utilized once potential cross-reactive epitopes are 
identified. 
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